



Bwrdd Iechyd Prifysgol Bae Abertawe Swansea Bay University Health Board



| Meeting Date | 25 th May 2021 | Agenda Item | 2.1 | | | |
|----------------|---|-----------------------------------|-----------------|--|--|--|
| Report Title | Integrated Performance Rep | ort – Year End | | | | |
| Report Author | Darren Griffiths, Director of Fin | | ce (interim) | | | |
| Report Sponsor | Darren Griffiths, Director of Fin | | | | | |
| Presented by | Darren Griffiths, Director of Finance and Performance (interim) | | | | | |
| Freedom of | Open | | | | | |
| Information | | | | | | |
| Purpose of the | The purpose of this report is to | provide an update o | on the current | | | |
| Report | performance of the Health Bo | ard at the end of the | e most recent | | | |
| | reporting window in delivering | key local performan | ce measures | | | |
| | as well as the national measure | ures outlined in the 2 | 2020/21 NHS | | | |
| | Wales Delivery Framework. | | | | | |
| | | | | | | |
| | For the May Committee the rep | | • | | | |
| | full year report pack for the Co | | | | | |
| | more detailed one off report | | itation will be | | | |
| | provided to the Quality and Sa | tety Committee. | | | | |
| Kaylaayaa | From the 1st April 2020 DAC | rating has not have | applied to the | | | |
| Key Issues | From the 1 st April 2020, RAG | | | | | |
| | targeted intervention priorities | | | | | |
| | actions within the 2020/21 anr progressed due to the COVID- | - | low not being | | | |
| | progressed due to the COVID- | re panuemic. | | | | |
| | Once the final deliverable | argets are agreed | for 2021/22 | | | |
| | consideration will be given to | | | | | |
| | technique to support the imp | 5 | | | | |
| | Management Framework. | | | | | |
| | | | | | | |
| | The key issues set out in this r | eport are: - | | | | |
| | | • | | | | |
| | Emergency Department | ED) attendances in | March 2021 | | | |
| | were 32% higher than Febru | ary 2021 and this inc | reasing trend | | | |
| | continued into April 2021. | | | | | |
| | • ED 4-hour performance in | • | March 2021 | | | |
| | compared to 71.3% in Febr | uary 2021. | | | | |
| | • 12-hour waits in March 2 | • | ` ' | | | |
| | February 2021 however 1- | | | | | |
| | broadly static (219 in Febru | - | , | | | |
| | • GP referrals into the RTT | 5 | | | | |
| | since the first wave of the | | · · | | | |
| | pandemic levels. As a conse | | | | | |
| | list size across the RTT syst | | ` | | | |
| | size now 73,238 from 54,30 | / in February 2020). ⁻ | I his excludes | | | |
| | 8 week diagnostic waits. | | | | | |

| | from its peak increased for patients over • SCP perform 2021 by 12% March 2021 required to re • Sickness ab the Decembe • Mental Hea Measures co achieved in | at the end of J r the last four 63 days as op nance fell betw 6 but was fore (unvalidated fi educe backlog t sence levels h er 2020 in-mont Ith - performar ontinues to be March 2021. | CP) backlog has re lanuary 2021, but the weeks and now s posed to 285 four we veen January 2021 cast to recover by a igure) to 61.8%. Fu to a sustainably delive have improved consist th peak. Ince against the M e maintained. All Psychological ther target access levels | e backlog has tands at 356 eeks ago. and February at least 6% in orther work is verable level. iderably since fental Health targets were apies access |
|-----------------|---|---|--|---|
| Specific Action | Information | Discussion | Assurance | Approval |
| Required | \checkmark | | \checkmark | |
| Recommendations | Members are as | ked to: | | |
| | • NOTE the H and targets. | ealth Board pe | erformance against k | key measures |

INTEGRATED PERFORMANCE REPORT – YEAR END

1. INTRODUCTION

The purpose of this report is to provide an update on current performance of the Health Board at the end of the most recent reporting window in delivering key performance measures outlined in the 2020/21 NHS Wales Delivery Framework and local quality & safety measures.

2. BACKGROUND

The 2020/21 NHS Wales Delivery Framework sets out the 78 measures under the quadruple aims which the performance of the Health Board is measured. The aims within the NHS Delivery Framework are:

- **Quadruple Aim 1**: People in Wales have improved health and well-being with better prevention and self-management
- Quadruple Aim 2: People in Wales have better quality and more accessible health and social care services, enabled by digital and supported by engagement
- **Quadruple Aim 3**: The health and social care workforce in Wales is motivated and sustainable
- Quadruple Aim 4: Wales has a higher value health and social care system that has demonstrated rapid improvement and innovation, enabled by data and focused on outcomes

The Health Board's performance reports have traditionally been structured according to the aims within the NHS Delivery Framework however, the focus for NHS Wales reporting has shifted to harm management as a consequence of the COVID-19 pandemic. In order to improve the Health Board's visibility of measuring and managing harm, the structure of this report has been aligned with the four quadrants of harm as set out in the NHS Wales COVID-19 Operating Framework and the Health Board's Q2 Operational Plan. The harm quadrants are illustrated in the following diagram.

| Harm from Covid itself | Harm from overwhelmed NHS and social care system |
|-----------------------------|---|
| Harm from reduction in non- | Harm from wider societal |
| Covid activity | actions/lockdown |

Appendix 1 provides an overview of the Health Board's latest performance against the Delivery Framework measures for the 2020/21 financial year, along with key local quality and safety measures. A number of local COVID-19 specific measures have been included in this iteration of the performance report and further work will be undertaken over the next quarter to introduce additional measures that will aid in measuring harm in the system.

The traditional format for the report includes identifying actions where performance is not compliant with national or local targets as well as highlighting both short term and long terms risks to delivery. However, due to the operational pressures within the Health Board relating to the COVID-19 pandemic, it was agreed that the narrative update would be omitted from this performance report until operational pressures significantly ease. Despite a reduction in the narrative contained within this report, considerable work has been undertaken to include additional measures that aid in describing how the healthcare system has changed as a result of the pandemic.

3. GOVERNANCE AND RISK ISSUES

Appendix 1 of this report provides an overview of how the Health Board is performing against the National Delivery measures and key local measures. Mitigating actions are listed where performance is not compliant with national or local targets as well as highlighting both short term and long terms risks to delivery.

4. FINANCIAL IMPLICATIONS

At this stage in the financial year there are no direct impacts on the Health Board's financial bottom line resulting from the performance reported herein.

5. RECOMMENDATION

Members are asked to:

• **NOTE**- current Health Board performance against key measures and targets set out within this year-end report

| Governance an | nd Assurance | | | | |
|---|--|-------------|--|--|--|
| Link to | Supporting better health and wellbeing by actively prom | oting and | | | |
| Enabling | empowering people to live well in resilient communities | 5 | | | |
| Objectives | Partnerships for Improving Health and Wellbeing | \boxtimes | | | |
| (please | Co-Production and Health Literacy | \boxtimes | | | |
| choose) | Digitally Enabled Health and Wellbeing | \boxtimes | | | |
| | Deliver better care through excellent health and care services | S | | | |
| | achieving the outcomes that matter most to people | - | | | |
| | Best Value Outcomes and High Quality Care | \boxtimes | | | |
| | Partnerships for Care | \boxtimes | | | |
| | Excellent Staff | \boxtimes | | | |
| | Digitally Enabled Care | \boxtimes | | | |
| | Outstanding Research, Innovation, Education and Learning | | | | |
| Health and Car | | | | | |
| (please | Staying Healthy | \square | | | |
| choose) | Safe Care | \square | | | |
| | Effective Care | \square | | | |
| | Dignified Care | \square | | | |
| | Timely Care | \square | | | |
| | Individual Care | \boxtimes | | | |
| | Staff and Resources | | | | |
| Quality Safety | and Patient Experience | | | | |
| The performance report outlines performance over the domains of quality and safety and patient experience, and outlines areas and actions for improvement. Quality, safety and patient experience are central principles underpinning the National Delivery Framework and this report is aligned to the domains within that framework. There are no directly related Equality and Diversity implications as a result of this report. | | | | | |
| Financial Impli | cations | | | | |
| Financial Implications At this stage in the financial year there are no direct impacts on the Health Board's financial bottom line resulting from the performance reported herein. | | | | | |
| Legal Implicati | ons (including equality and diversity assessment) | | | | |
| | dicators monitor progress in relation to legislation, such as the | ne Mental | | | |
| Staffing Implica | ations | | | | |
| A number of ind Personal Devel | licators monitor progress in relation to Workforce, such as Sick opment Review rates. Specific issues relating to staffing idually in this report. | | | | |

Long Term Implications (including the impact of the Well-being of Future Generations (Wales) Act 2015)

The '5 Ways of Working' are demonstrated in the report as follows:

- Long term Actions within this report are both long and short term in order to balance the immediate service issues with long term objectives. In addition, profiles have been included for the Targeted Intervention Priorities for 2019/20 which provides focus on the expected delivery for every month as well as the year end position in March 2020.
- **Prevention** the NHS Wales Delivery framework provides a measureable mechanism to evidence how the NHS is positively influencing the health and wellbeing of the citizens of Wales with a particular focus upon maximising people's physical and mental well-being.
- Integration this integrated performance report brings together key performance measures across the seven domains of the NHS Wales Delivery Framework, which identify the priority areas that patients, clinicians and stakeholders wanted the NHS to be measured against. The framework covers a wide spectrum of measures that are aligned with the Well-being of Future Generations (Wales) Act 2015.
- **Collaboration** in order to manage performance, the Corporate Functions within the Health Board liaise with leads from the Service Groups as well as key individuals from partner organisations including the Local Authorities, Welsh Ambulance Services Trust, Public Health Wales and external Health Boards.
- **Involvement** Corporate and Service Group leads are key in identifying performance issues and identifying actions to take forward.

| Report History | The last iteration of the Integrated Performance Report was |
|----------------|---|
| | presented to Performance & Finance Committee in March 2021. |
| | This is a routine monthly report. |
| Appendices | Appendix 1: Integrated Performance Report |
| | |



Appendix 1- Integrated Performance Report May 2021




CONTENTS PAGE

| | | Page number(s): |
|----|---|-----------------|
| 1. | QUADRANTS OF HARM SUMMARY | 9 |
| 2. | REPORT CARDS | |
| | 2.1 Harm from overwhelmed NHS and Social Services | 10-55 |
| | 2.2 Harm from reduction in non-COVID activity | 56-79 |
| | 2.3 Harm from wider societal actions/lockdown | 80-87 |
| 3. | FINANCE | 88-90 |
| 4. | APPENDIX 1: INTEGRATED PERFORMANCE DASHBOARD | 91-95 |

1. QUADRANTS OF HARM SUMMARY


The following is a summary of all the key performance indicators included in this report.




NB- RAG status is against national or local target ** Data not available

*RAG status based on in-month movement in the absence of local profiles

2. REPORT CARDS 2.1 HARM FROM OVERHWELMED NHS AND SOCIAL SERVICES



| Ho | w are we doing? |
|----|---|
| • | The Health Board's Category A (Red response) was 73% in March 2021, which exceeds the National shared target of 65% and represents an improvement of circa 3 % per month since January 2021. Red call demand was 321, an increase of 34 red calls compared to February. |
| • | 1 hour ambulance handover performance has seen a marginal deterioration versus the February position, though still better than the large number of >1 hr handover delays reported Sept – Dec 2020. The total number of ambulance delays > 1 hr was 231, this equates to 5% of patients experiencing a delay at the front door of greater than 1 hour. |
| , | Ambulance demand for March 2021 was 4413, an increase of 144 when compared to February activity. Demand has ranged between 3918 and 4778 over the last 10 month period. |
| Nr | at actions are we taking? |
| | Implementing an OPAS service adjacent to Morriston Emergency Department (ED) and thus improve care for frail elderly patients and release ED trolley capacity to support timely patient handover. |
| • | Surge capacity open in all hospital sites to support urgent care flows and ambulance handover. |
| , | Improved focus, reporting and escalation of the clinically optimised patient group that impacts capacity and flow on all of the sites. |
| | Implementation of the full time Patient Flow Co-ordinators role in Morriston Hospital to work in partnership with the ambulance triage nurse in respect of handover, monitoring of patients and staffing of ambulance handover capacity within the Emergency Department. |
| • | More consistent application of the 'Fit to Sit' policy with the above roles in place. |
| , | Adoption of good communication and escalation of flow/handover challenges with the Operational Delivery Unit. |
| , | Continuation of the Level 1 falls vehicle with St Johns' to reduce the conveyance of patients to hospital following a fall. |
| • | Falls rapid response car with the Welsh Ambulance Service Trust (WAST) Health Board Clinical Lead and Physiotherapist to respond to falls at home-aimed at admission avoidance. |
| • | Daily review of the ambulance stack by GP's to reduce ambulance conveyance demand and seek alternative pathways for patients. |
| , | Singleton hospital to provide the downgraded 999 and treat and transfer pathways to redirect appropriate demand. |
| | Promotion of the GP advice for ambulance paramedics linked to the Acute GP Unit (AGPU) based in Singleton Hospital. |
| Vr | at are the main areas of risk? |
| | Ambulance resourcing to respond to demand within the 8 minute response time. |
| | Hospital and social care system wide patient flow and discharge constraints which impact upon the Emergency Department's ability to receive timely |
| | handover. This results in increased risk to patients in the community and at hospital if there are prolonged ambulance handover times. |
| | Reduced acute capacity due to COVID outbreaks, particularly on the Morriston site and the impact of this on ED outflow and ambulance handover. |
| ło | w do we compare with our peers? |
| , | The Health Board achieved 73% Category A performance response in March 2021, the best performing Health Board area in Wales. |
| , | The Health Board performance for >1 hour handover delays is exceeded only by Cwm Taf Morgannwg and Cardiff and Vale, with markedly poorer |



| _ | w are we doing? |
|----|---|
| | Unscheduled care performance against the 4 hour target in March 2021 was 76.9%, >5% improvement on the February position. |
| • | 4 hr performance over the past 6 month period has been relatively static at 71-77%. |
| , | There has been a sustained reduction in the number of patients spending more than 12 hours in the Emergency Department with a reported March position |
| | of 457, 77 less patients than the February position. |
| | During March 2021 4hr and 12hr performance improved compared to the previous reporting period, against a background of increasing activity. |
| , | There is marked increase in activity in March 2021, with total attendances of 8839 between NPT Minor Injury Unit (MIU) and Morriston Emergency |
| | Department (ED), an increase of 24% compared to the February activity of 6677 attendances. |
| Vł | nat actions are we taking? |
| | Introduction of revised system escalation processes to ensure risk balanced approach to demand management. |
| | Surge capacity open and staffed across all hospital sites to support urgent care flows. |
| | Ongoing recruitment to vacancies critical to delivery of unscheduled care services across the Health Board – in progress. |
| | Improved focus on the clinically optimised patient group, improved reporting and escalation processes in place. |
| | Securing additional medical and nursing workforce to support front door services- combination of block booking and ad hoc cover requests - in place. |
| | Ring-fenced planned care pathways with complete separation from the unscheduled care bed pool. Emergency Care Manager of the Day model introduced in Morriston to support the Patient Flow function. |
| | '111 First' step 1 launched in February 2021 to redirect patients into appropriate pathways of care, thus avoiding ED attendance. |
| • | Improved 'direct to specialty pathways' being developed with clinical and managerial leads. |
| | |
| VI | nat are the main areas of risk? |
| | Closed beds for Infection Prevention Control. |
| , | Capacity gaps in Care Homes, Community Resource Teams and capacity and fragility of private domiciliary care providers, leading to an increase in the |
| | number and length of wait of patients in hospital who are 'discharge fit'. The increasing number of discharge fit patients is impacting the outflow from the EE |
| | and thus ability to support timely ambulance handover. |
| | Sustainably staffing the high level of surge beds in the system remains a key operational challenge. |
| | Workforce - with ongoing challenges in general nursing and medical roles in some key specialities and service areas such as the Emergency Department. |
| | |
| | Loss of in-patient capacity on the Morriston site due to COVID ward outbreaks continues to further impact patient flow on site. |
| | |
| | |
| | |
| | Loss of in-patient capacity on the Morriston site due to COVID ward outbreaks continues to further impact patient flow on site. |
| 10 | Loss of in-patient capacity on the Morriston site due to COVID ward outbreaks continues to further impact patient flow on site. |
| Ho | Loss of in-patient capacity on the Morriston site due to COVID ward outbreaks continues to further impact patient flow on site. |

| Quadrant Of Harm: | | om overwhelmed NHS and social care system. | | | | | | F) | ExecutiveRichLead:Dire | | | | |
|--|----------------------|---|------------------|------------|------------|------------|--------------------|--------------|------------------------|-----------------|-----------------------|------------------------------|---|
| Quadruple Aim: | | adruple Aim 2 - People in Wales have better quality and more accessible alth and social care services, enabled by digital and supported by | | | | | | | е | Annual | Period: February 2021 | | |
| | health ai engagen | | care serv | ices, en | abled by | digital an | d supporte | ed by | | Plan Profile | | ent Status ainst target): | (12 month trend |
| Prompt orthogeria hours of presentati | | nent- % r | patients r | eceiving | an asses | ssment b | y a senior | geriatrician | within | | | | ↑ ● |
| (2) Prompt surgery - % | % patients | Indergoir | ig surger | y the day | following | g presen | tation with | hip fracture | | | | | ↓ ● |
| (3) NICE compliant surgery - % of operations consistent with the recommendations of NICE CG124 | | | | | | | | 1 | | | | ↓ ● | |
| (4) Prompt mobilisation | on after sur | gery - % p | patients o | out of be | d (standir | ng or hois | sted) by the | e day after | | | | | ↑ ● |
| (5) Not delirious when | tested- % | patients (| <4 on 4 <i>F</i> | VT test) v | vhen test | ed in the | week afte | r operation | | | | | ↑ ● |
| (6)Return to original ro 120 day follow-up | esidence- 9 | 6 patients | s dischar | ged back | to origin | al reside | nce, or in t | hat residen | ce at | | | | ↑ ● |
| 7) 30 day mortality ra | ite | | | | | | | | | | | | ↓ ● |
| | | | | womst | on nosp | ital com | pliance aç | jainst NOF | measu | es | | | |
| 100% 80% 60% | /o | | | | | | | | | | | | Measure 1 Measure 2 Measure 3 |
| 80% | /o | | | | | | | | | | | | Measure 2 |
| 80% 60% | | | | | | | | | | | | | Measure 2 Measure 3 |
| 80% 60% 40% | % | Mar-20 | Apr-20 | /lay-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | 000 | Dec-20 | Jan-21 | | Measure 2 Measure 3 Measure 4 |
| 80% 60% 40% 20% | | Mar-20 | Apr-20 | May-20 | Jun-20 | | 02-6nV chmarkin | | | Dec-20 | Jan-21 | - | Measure 2 Measure 3 Measure 4 Measure 5 Measure 6 |
| 80% 60% 40% 20% | | Mar-20 | Apr-20 | May-20 | Jun-20 | | 02-6ny chmarkin | | 0.22 | | Jan-21 | | Measure 2 Measure 3 Measure 4 Measure 5 Measure 6 |

| Measure | Period | Morriston | All-Wales | England, Wales & N. Ireland |
|---------------------------------------|--------|-----------|-----------|--------------------------------|
| (1) Prompt orthogeriatric assessment | Feb-21 | 87.6% | 59.9% | 86.3% |
| (2) Prompt surgery | Feb-21 | 56.3% | 67.6% | 68.7% |
| (3) NICE compliant surgery | Feb-21 | 71.2% | 73.0% | 70.6% |
| (4) Prompt mobilisation after surgery | Feb-21 | 74.1% | 75.5% | 80.8% |
| (5) Not delirious when tested- | Feb-21 | 75.2% | 55.4% | 57.7% |
| (6)Return to original residence | Jan-21 | 73.7% | 73.6% | 69.8% |
| (7) 30 day mortality | Dec-20 | 8.4% | 7.3% | 8.2% |

Source: National Hip Fracture Database

<u>Measure 1</u> Prompt orthogeriatric assessment <u>Measure 2</u> Prompt surgery <u>Measure 3</u> NICE compliant surgery <u>Measure 4</u> Prompt mobilisation after surgery <u>Measure 5</u> Not delirious when tested <u>Measure 6</u> Return to original residence. <u>Measure 7</u> 30 day mortality rate

How are we doing?

- 1. The current orthogeriatric medical establishment <1 WTE equivalent split between: 1 Consultant, 1 Associate Specialist and 1 Specialty Doctor. Specialty Doctor is retiring Aug 2021. Frailty Business Case has been developed to support the recommended Orthogeri staffing model further.
- 2. Hip fracture patients are operated on as a priority over fitter and younger trauma patients that are stable, but the lack of trauma capacity restricts doing all in a timely fashion particularly the inability to upscale when there is a spike in activity. There is a trauma list running 8am-8pm every day (incl. weekends and bank holidays). Additional Trauma theatre capacity has been provided which has assisted in meeting the target and can be seen in the figures below. However, the additional Trauma theatre capacity has is shared between Orthoplastics and Spines which on occasions results in #NOF patients not getting to theatre within the NHFD target.
- 3. Surgical procedure consistent with the recommendations of NICE CG124.
- 4. All patients receive a physio assessment within 24hours of surgery Mon-Fri. Data is captured for all patients who do not sit out of bed Mon-Fri e.g. low haemoglobin, low blood pressure.
- 5. The overall performance has improved in the last twelve months with significant improvement on the not delirious post-op.

What actions are we taking?

- 1. Part time orthogeriatric Associate Specialist's contract has been increased by 2 sessions per week.
- 2. NICE compliant surgery process being monitored through monthly audit/governance meetings performance is improving which is encouraging.
- 3. Funding secured to appoint additional weekend physic cover for #NOF patients; service commenced in Jan 20 and impact is being monitored. Additional weekend support is required and will be covered in the IMTP bid for 2020-21. Work being undertaken to train nursing staff in mobilising patients and provide additional resources for physiotherapy to support the early mobilisation of patients, particularly on the weekend.
- 4. Further improvement is required in relation to greater involvement of rehabilitation sites in pathway discussions and planning. Ensuring that a conversation about home circumstances, improved use of discharge planning sheets to capture family / patient discussions about expected destination on discharge and involving social workers (when appropriate) at an early stage, are priorities.
- 5. GIRFT recommendations are included in the Frailty Business Case, which is in discussion with Morriston Unit and Executive team.
- 6. Regular #NOF multi-disciplinary meetings are in place so that performance and service improvement is monitored in detail.
- Bi monthly •Audit meetings Bi Monthly Business meetings •Monthly Exec meetings •Fortnightly performance 'look back' meetings •Monthly Meeting held with Emergency Dept. stakeholders
- 7. Regular audits are undertaken in all elements of the pathway and presented to the Unit so that service improvement is monitored and promoted.
- 8. Detailed data is now collected in house so that every patients journey is not only captured but also analysed at the fortnightly 'look back' meetings.
- 9. All #NOF patients are discussed as a matter of priority at the 7:30 trauma meeting.
- 10. MDT working is encouraged in the fortnightly and monthly #NOF meetings. Meetings include a wide invitation of stakeholders who are encouraged to attend the regular meetings as well as specific service improvements events and discussions
- 11. The case for increasing the number of Orthogeriatrician by 2 posts is being made through the Frailty Business Case.

What are the main areas of risk?

30-day mortality has improved but remains a key issue and the outcomes and mortality data are reviewed at the departmental arthroplasty meetings. All cases of mortality are cross-referenced with the department's morbidity and mortality database and presented at the monthly meeting to review any points for learning. The case for increasing the number of Orthogeriatrician by 2 posts is being made through the Frailty Business Case.

How do we compare with our peers?

• Included within the benchmarking table above.

| | STROKE | | | | |
|------------------------------------|--|------------------------------------|---|--|--|
| Quadrant Of Harm: | Harm from overwhelmed NHS and social care system. | Executive Lead: | Rab McEwan Officer | , Interim Chief | Operating |
| Quadruple Aim: | Quadruple Aim 2 - People in Wales have better quality and more accessible | Annual | Period: March 2 | | larch 2021 |
| | health and social care services, enabled by digital and supported by engagement | Plan Profile | WG Target | Current Status (against target): | Movement (12 month trend) |
| Measure 1: % of pati | ents who have a direct admission to an acute stroke unit within 4 hours | N/A | 59% | X | ↓ ● |
| Measure 2: % of thro 45 minutes | ombolysed stroke patients with a door to door needle time of less than or equal to | N/A | 12 ↑ trend | ✓ | ↑ ● |
| Measure 3: % of pati | ents who receive a CT scan within 1 hour | N/A | 55% | × | ↓ ● |
| Measure 4: % of pati hours | ents who are assessed by a stroke specialist consultant physician within 24 | N/A | 95% | ✓ | ↑ ● |
| Measure 5: % of pati | ents receiving the required minutes for speech and language therapy | N/A | 12 ↑ trend | \checkmark | ↑ ● |
| | | | Benc | hmarking | • |
| 80% | | | | rch 2021 | |
| 60% 40% 20% | | Quality Improvement Measures | 1. Direct Admissic to Acute Stroke Unit < 4 hours | Stroke | 5. Patients receiving minutes for SALT |
| 0% 🔶 | | AB | 40.0% | 97.2% | 58.0% |
| Mar-20 | May-20 Jun-20 Jun-20 Sep-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 | BCU | 21.1% | 83.0% | 42.3% |
| Mar | Auc | C&V CTM | 4.5% | 75.0% | 63.7% 32.4% |
| | | Hywel Dda | 38.3% | 96.4% | 40.0% |
| | 4 hours direct admission | SBU | 20.4% | 100.0% | 55.9% |
| | Thrombolysed patients <= 45 mins CT within 1 hour | All-Wales | 22.6% | 87.6% | 43.7% |

| | oke unit within 4 hours. <u>Measure 2:</u> % of thrombolysed stroke patients with a door to door nts who receive a CT scan within 1 hour. <u>Measure 4:</u> % of patients who are assessed by a eceiving the required minutes for speech and language therapy |
|---|---|
| How are we doing? | |
| admissions over the last 4 weeks to a stroke unit bed within 4 hours and Covid. 100% was achieved for the end of March 2021 for a assessment. Our access to CT scanning within 1 hour has improved to Covid, however there is still room for improvement. | March 2021 (target 59%), following a drop in performance due to Covid pressures. Direct continues to be under target at 20.4%, which is mainly due to unscheduled care pressures ssessment by a Consultant and 93.9% compliance achieved for Physio, OT and SALT to 40.8% in March 2021, from 30.6% in February 2021, despite the ongoing pressures due lity to make the desired improvements, and unscheduled care pressures/Covid have also |
| What actions are we taking? | |
| identify opportunities for improvement. Medical cover for Stroke patients is provided by the General N 24 hours. The additional medical staffing reported previously has all which these colleagues have to cover, therefore not allowing them the junior gaps in rota and looks to sustainable recruitment in a diffic part of the Hyper-acute Stroke Unit (HASU) business case developr An Early Supported Discharge team has been developed and implet | nented recently, however, it has limited therapies cover and lack of support staff, as well as |
| | ead therapist to be considered in the near future. ansea Bay University Health Board (SBUHB) is currently being developed for consideration work is led by the Medical Directorate management team, in conjunction with strategy. |
| What are the main areas of risk? | |
| Insufficient capacity and workforce resilience to support 7 day worki Not having a dedicated Stroke Consultant out of hour's rota. High volumes of work in Emergency Department preventing timely a Medicine bed deficit equates to approximately 50 beds which prevent Unscheduled care pressures and increasing waits for transfers of care Limited availability to the thrombectomy pathway represents a risk to | nts ring fencing of ASU beds to facilitate timely admissions. re affecting stroke care capacity. |
| How do we compare with our peers? | |
| SBUHB is one of the main acute stroke care providers in Wales whi stroke work. SSNAP report for March 2021 shows Morriston with comparative str | ch allocates general medicine workload to Stroke Physicians – detracting from acute oke performance in some domains to most Welsh hospitals, but not others (cat C). t of hours cover and improved ring fenced / dedicated stroke beds in order to deliver |
| | |

| | | | | | | E | E. CO | LI Ba | cterae | emia | | | | |
|---|---|--------------------|-----------------|----------|-----------------------|-----------------|------------------------|----------|--------------------|-------------------|---|--|---|--|
| Quadrant of Harm: | Harm f | rom overv | whelme | ed NHS | and so | ocial ca | are syst | em. | | | Executive Lead: | | iams, Interim Dire tient Experience | ctor of |
| Quadruple Aim: | Quadru | uple Aim 2 | 2 - Peor | ple in V | Vales h | ave be | etter qu | ality an | nd more | e | Annual | | Period: Ma | rch 2021 |
| | accessible health and social care services, enabled by digital and supported by engagement. easure 1: Cumulative rate of E <i>.coli</i> bacteraemia cases per 100,000 of the population | | | | | | | | Plan Profile | WG Target | Current Status (against profile): | Movement: (12 month trend) | | |
| Measure 1: Cumulativ | e rate of | E <i>.coli</i> bac | teraem | ia case | es per 1 | 00,000 |) of the | popula | ation | | N/A | N/A | | 1 |
| Measure 2: Number of | f E <i>.coli</i> ba | acteraemi | a cases | S | | | | | | | N/A | N/A | | 1 |
| (1) | Rate of | f E.coli b | acterae | emia p | er 100, | 000 of | the po | pulati | on | | | Bench | marking | |
| 25 0 0 7- Inter V V E.Coli Rate per | Jun-20 Jun-20 | | 02-50 BU HB) | Sep-20 | 07 t20 Cumulati | 07-70 Nov-50 | 07-59 Q oli Rate | per 100 |)Kbob (; feb-21 | Mar-21 BBU HB) | LHB Wales SBU | Cumulative Cases (Apr 20 - Mar-21) 1882 241 | Cumulative Rate (Apr 20 - Mar 21) 59.9 61.89 | Rank (Cumulative Rate) - 3 |
| | | | | | | | | | | | AB | 295 | 49.9 | 1 |
| | (2 | 2) Numbe | Prote. | coll ba | cterae | mia ca | ises | | | | BCU | 440 | 63 | 4 |
| 40 | | | | | | | | | | | C&V | 280 | 56.4 | 2 |
| - | | | | | | | | | | | CTM | 316 | 70.53 | 5 |
| 30 | | | | | | | | | | | Hdda | 299 | 77.54 | 6 |
| 20 10 9 4 br-20 0 0 0 0 0 0 | May-20 | Jun-20 Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | | | | |
| | | Nur | mber E.C | Coli cas | es (SBL | J HB) | | | | | | Public Health Wal Dashboard (April | es: Healthcare Ac 2021) | quired |

Measure 1: Rate of E.coli bacteraemia cases per 100,00 of the population Measure 2: Number of E.coli bacteraemia cases

How are we doing?

- In 2020/21, there had been 241 cases of *E. coli* bacteraemia within the Health Board. This was 24% fewer than the number of cases in the previous year. The cumulative cases for 2020/21 was 59 cases below the projected IMTP profile and 11 cases below the Welsh Government infection reduction expectation for the Health Board.
- There were 28 cases of *E. coli* bacteraemia in March 2021; this was 5 cases above the IMTP monthly profile and 4 cases above the Welsh Government monthly infection reduction expectation.
- 66% of the cases in 2020/21 were considered community acquired; 34% were considered hospital acquired. Of the latter, 52% were associated with Morriston Hospital, 30% with Singleton Hospital, and 16% with Neath Port Talbot Hospital.
- In March 2021, 32% of cases were considered hospital acquired; of these, 56% were associated with Morriston Hospital, 33% with Singleton Hospital, and 11% with Neath Port Talbot Hospital.

What actions are we taking?

- Service Delivery Groups are monitoring staff training in relation to Standard Infection Control Precautions and ANTT training.
- Morriston Service Delivery Group has established a Consultant-led bacteraemia review group. Neath Port Talbot & Singleton Hospital Service Delivery Group is establishing a Service Group IPC Group, plus a Divisional Ward Manager IPC group, which feeds into the main IPC Group, which will monitor Tier 1 hospital acquired infections.

What are the main areas of risk?

- A large proportion of *E. coli* bacteraemia is community acquired, with many patient related contributory factors, particularly in relation to urinary tract infection and biliary tract disease. As such, it will be a challenge to prevent a significant proportion of these.
- Use of pre-emptive beds on acute sites increases risks of infection transmission.
- Bed occupancy, which is frequently close to, or exceeds, 90% is associated with an increased risk of hospital acquired infections.
- Reduction initiatives are compromised by high levels of service activity, staffing vacancies, and reliance on temporary staff.

How do we compare with our peers?

• The Health Board cumulative incidence of E. coli bacteraemia per 100,000 population for 2020/21 was 61.89, the third lowest incidence in NHS Wales.

• The incidence in March 2021 was 84.67/100,000 population; this was the third highest monthly incidence for the major acute Health Boards in Wales.

| | | | | | | S. A | UREU | IS Bad | cterae | emia | | | | |
|--|------------------|-------------------|------------|----------------|---------|-------------|--------------|----------|--------|------------|-------------------|---------------------------------------|--|----------------------------------|
| Quadrant of Harm: | Harm fr | om over | whelme | d NHS | and so | cial ca | re syste | em. | | | Executiv Lead: | | Villiams, Interim D Patient Experienc | |
| Quadruple Aim: | | | | | | | | | | accessible | Annua | | Period: Mar | ch 2021 |
| | engage | nd socia ment. | al care s | | s, enab | | | ina sup | portea | БУ | Plan Profile | WG | Current Status (against profile): | Movement: (12 month trend) |
| Measure 1: Cumulative | | | | | ses per | 100,00 | 00 of th | e popu | lation | | N/A | N/A | | ↑ 🔴 |
| Measure 2: Number of | | | | | | | | | | | N/A | N/A | | ↑ 🔴 |
| 60 | Rate of S | aureus | bacter | aemia | per 10 | 0,000 c | of the p | opulat | ion | | | Benc | hmarking | |
| 50 40 30 20 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | May-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | LHB | Cumulative Cases (Apr 20 - Mar-21) | | Rank (Cumulative |
| ∑ ₹ | | ureus Ra | ite per 10 |)0k pop | (ABMU | up to N | /lar-19) | <u>ب</u> | ŭ. | Σ | Wales SBU | 780 | 24.85 31.59 | Rate) - 6 |
| | (2) | Number | of S.au | <i>ireus</i> b | oactera | emia c | ase | | | | AB BCU | 157 | 26.56 | 5 |
| | | | | | | | | | | | C&V | 157 130 | 22.48 | 1 4 |
| 20 | | | | | | | | | | | CTM | 116 | 26.06 | 3 |
| 15 | | | | _ | | | | | | | Hdda | 94 | 24.38 | 2 |
| 01 01 01 01 01 01 01 01 01 01 01 01 01 0 | May-20 Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | | | · | |
| | | Number | er S.Aure | eus case | es (SBU | HB) | | | | | | Public Health W s Dashboard (A | /ales: Healthcare / oril 2021) | Acquired |

Measure 1: Rate of S.aureus cases per 100,00 of the population Measure 2: Number of S.aureus cases

How are we doing?

- In 2020/21, there had been 122 cases of Staph. aureus bacteraemia within the Health Board. This was 8% fewer than the number of cases in the previous year. The cumulative cases for 2020/21 was 2 cases above the projected IMTP profile and 50 cases above the Welsh Government infection reduction expectation for the Health Board. Three of these cases were MRSA bacteraemia, of which two were identified in Morriston and one was a community-acquired infection. There had been an 81% reduction in the number of MRSA bacteraemia cases in 2020/21 compared with the preceding financial year. This is a significant achievement, with the lowest incidence of MRSA bacteraemia in NHS Wales.
- There were 11 cases of *Staph. aureus* bacteraemia in March 2021; this was 5 cases above the IMTP monthly profile and the Welsh Government monthly infection reduction expectation.
- 52% of the cases in 2020/21 were considered community acquired; 48% were considered hospital acquired. Of the latter, 61% were associated with Morriston Hospital, and 36% with Singleton Hospital.
- In March 2021, 36% of cases were considered hospital acquired; of these, 50% were associated with Morriston Hospital, and 50% with Singleton Hospital.

What actions are we taking?

- Service Delivery Groups are monitoring staff training in relation to Standard Infection Control Precautions and ANTT training.
- Morriston Service Delivery Group has established a Consultant-led bacteraemia review group. Neath Port Talbot & Singleton Hospital Service Delivery Group is establishing a Service Group IPC Group, plus a Divisional Ward Manager IPC group, which feeds into the main IPC Group, which will monitor Tier 1 hospital acquired infections.

What are the main areas of risk?

- A significant proportion of *Staph. aureus* bacteraemia is community acquired, with many patient related contributory factors, such as recreational drug use, arthritis, chronic conditions, etc. As such, it is a challenge to prevent a significant proportion of these.
- Bed occupancy, which frequently is close to, or exceeds, 90%. Analysis by the Department of Health, reported in Tackling Healthcare associated infections through effective policy action (BMA, June 2009), suggested that when all other variables are constant, an NHS organisation with an occupancy rate above 90 per cent could expect a 10.3% higher MRSA rate compared with an organisation with occupancy levels below 85%.
- High bed turnover: in the same BMA report, the impact on MRSA rates of turnover intervals were suggested to have a greater impact on MRSA rates than bed occupancy levels.
- Reduction initiatives are compromised by high activity levels, staffing vacancies, and reliance on temporary staff.

- The Health Board cumulative incidence of *Staph. aureus* bacteraemia per 100,000 population for 2020/21 was 31.59, the highest incidence in NHS Wales, despite the incidence of MRSA bacteraemia being the lowest in Wales.
- The incidence in March 2021 was 33.26/100,000 population; this was the highest monthly incidence in Wales.

| | | | | | | | C.D | DIFFIC | ILE | | | | | |
|--------------------------------------|---------------------------------|-------------|----------|-----------|----------|----------|----------|-----------|---------|----------------|-----------------|--|---|---------------------------------|
| Quadrant of Harm: | Harm fro | m overw | helmed | NHS ar | nd soci | al care | e syster | n. | | | Executive Lead: | | Villiams, Interim D Patient Experiend | |
| Quadruple Aim: | Quadrup health ar engagen | nd social | | | | | | | | ccessible / | Annua Plan | l WG | Period: Ma | rch 2021 |
| | | | | | | | | | | | Profile | Target | Current Status (against profile): | Movement (12 month trend) |
| Measure 1: Cumulativ | | | cases p | er 100,0 | 0 of th | е рори | ulation | | | | N/A | N/A | | 1 |
| Measure 2: Number o | f C. difficile | cases | | | | | | | | | N/A | N/A | | \downarrow |
| (1 |) Rate of (| C. difficil | le cases | s per 10 | 0,000 | of the | popula | ation | | | | Bend | hmarking | |
| Mar-20 Apr-20 Apr-20 Apr-20 | May-20 Jun-20 | Jui-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | LHB Wales | Cumulative Cases (Apr 20 - Mar-21) 880 | Cumulative Rate (Apr 20 - Mar 21) 28.04 | Rank (Cumulative Rate) |
| C.Diff Rate | per 100k pop |) (SBU HE | 3) | Cur | nulative | e C.Diff | Rate pe | er 100k p | op (SBl | J HB) | SBU | 160 | 41.09 | 6 |
| | | (2) Nu | mber o | f C. diff | ficilo c | 2606 | | | • • | | AB | 146 | 24.69 | 2 |
| | | (2) 110 | | 0. 0.11 | | 4303 | | | | | BCU | 212 | 30.36 | 4 |
| 20 | | | | | | | | | | | C&V | 99 | 19.94 | 1 |
| 15 | _ | | _ | _ | _ | | | | | | CTM | 112 | 25.16 | 3 |
| 10 5 | | | | | | | | | | | Hdda | 138 | 35.79 | 5 |
| o Mar-20 Apr-20 | May-20 Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | | | | A |
| | | Numbe | | cases (S | B UHB |) | | | | | | Public Health W Dashboard (Ap | ales: Healthcare | Acquired |

Measure 1: Rate of *C. difficile* cases per 100,00 of the population Measure 2: Number of *C. difficile* cases

How are we doing?

- In 2020/21, there had been 160 cases of *C. difficile* within the Health Board. This was 16% higher than the number of cases in the previous year. The cumulative cases for 2020/21 was 43 cases above to projected IMTP profile and 64 cases above the Welsh Government infection reduction expectation for the Health Board. There were few episodes during the year of confirmed transmission of infection. The increase is cases may have been related to antimicrobial prescribing due to COVID-19.
- There were 12 *Clostridioides difficile* toxin positive cases in March 2021; this was 7 cases above the IMTP monthly profile and 4 cases more than the Welsh Government monthly infection reduction expectation.
- 65% of the cases in 2020/21 were considered hospital acquired. Of these, 59% were associated with Morriston Hospital, 26% with Singleton Hospital, 11% with Neath Port Talbot, 3% with Gorseinon Hospital and 1% with Cefn Coed Hospital.
- In March 2021, 58% of cases were considered hospital acquired; of these, 43% were associated with Morriston Hospital, 43% with Singleton Hospital and 14% with Neath Port Talbot Hospital.

What actions are we taking?

- Antimicrobial actions in Primary Care: <u>C. difficile pilot</u> community cases are being reviewed by an antimicrobial pharmacist. <u>Focus on 4C (broad-spectrum antibiotics)</u>, with a cluster-based approach. <u>Sore throat audit</u> agreed as the pre-qualifier for access to the Prescribing Management Scheme. <u>Presentation to Cluster leads</u> planned for May to discuss a proposal for a programme of practice-based antimicrobial quality improvement work.
- Antimicrobial actions in Secondary Care: <u>Introduction of a programme of junior-doctor led antimicrobial quality improvement projects</u> planned for this Spring. <u>ARK 72-hour mandatory review incorporated into the e-prescribing system roll-out for all antimicrobials</u>. <u>Focus on surgical prophylaxis</u>. Audits undertaken in Theatre Recovery areas. <u>Review placement of gentamicin within the Antimicrobial Guidelines</u>, with an aim of further reducing broad-spectrum <u>antibiotic usage</u>.
- Continued focus on the '4D' cleaning and decontamination programme, utilising Ultraviolet-C disinfection.
- Continued review of Service Delivery Group C. difficile improvement plans by the C. difficle Scrutiny Group.

What are the main areas of risk?

- Contributory factors: antibiotic prescribing; impact of COVID-19 on antimicrobial prescribing; lack of decant facilities, which restricts ability to undertake deepcleaning of clinical areas.
- *C. difficile* spores may be found in 49% rooms of patients with *C. difficile* infection; 29% rooms of asymptomatic carriers.
- The current ratio of *C. difficile* carriers to *C. difficile* infection cases is approximately 2:1. In all cases where there are patients who are either carriers of, of infected with, *C. difficile*, it is critical that the care environment is thoroughly deep cleaned using the '4D' cleaning/decontamination process if the safety of the care environment is not to be compromised. To facilitate this, decant facilities and appropriately funded cleaning hours are priorities.
- Reduction initiatives are compromised by increased activity and where activity levels are such that it is not possible to decant bays to clean effectively patient areas where there have been infections.

- The Health Board cumulative incidence per 100,000 population for 2020/21 was 41.09, the highest incidence in NHS Wales.
- The incidence in March 2021 was 36.29/100,000 population; this was the second highest monthly incidence in Wales, and was more than twice the incidence in the best-performing Health Board.
- There has to be continued and significant improvement in relation to antimicrobial prescribing if Health Board performance is to be comparable with peers.

| | | | | | Klebsi | ella s | рр. <i>В</i> | actera | aemia | | | | |
|--|------------------------|------------|------------------|------------|------------|-----------|--------------|----------|--------|--------------------------|---------------------------------------|---|----------------------------------|
| Quadrant of Harm | Harm from | n overwhe | elmed NHS | and soc | ial care | system | 1. | | | Executiv Lead: | | Villiams, Interim Patient Experien | |
| Quadruple Aim: | | | People in V | | | | | | | | | Period: Ma | rch 2021 |
| | health and engageme | | are service | s, enable | ed by dig | gital and | d suppo | orted by | / | Annua Plan Profile | Target | Current Status (against profile): | Movement: (12 month trend) |
| Measure 1: Cumulativ | ve rate of Kle | bsiella sp | p. bacterae | emia cas | es per 1 | 00,000 | of the | populat | tion | N/A | N/A | | ↑ 🔴 |
| Measure 2: Number o | | | | | | | | | | N/A | N/A | | 1 |
| (1) R | ate of Klebs | siella spp | b. bacterae | mia per | 100,00 | 0 of the | e popul | lation. | | | Benc | hmarking | |
| 20 15 10 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | May-20 Jun-20 | Jul-20 | Aug-20 Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | LHB | Cumulative Cases (Apr 20 - Mar-21) | | Cumulative |
| 2 < | ΣΓ | , | δ Þ | 0 | Z | Δ | 7 | ш | 2 | Wales | 620 | 19.75 | - |
| Klebsiella Rate | per 100k pop | (SBU HB) |) — Cur | nulative k | Klebsiella | a Rate pe | er 100K | pop (SB | U HB) | SBU | 102 | 26.2 | 4 |
| | (2) Ni uzala | | ahaialla a | nn haa | | | | | | AB | 116 | 19.62 | 5 |
| | (2) NUMD | | ebsiella s | pp. bac | teraen | nia cas | ses | | | BCU | 129 | 18.47 | 6 |
| 20 | | | | | | | | | | C&V | 100 | 20.14 | 3 |
| | | | | | | | | | | CTM | 96 | 21.56 | 2 |
| 15 | | | | | | | | | | Hdda | 73 | 18.93 | 1 |
| 00 War-20 Apr-20 A | May-20 Jun-20 | Jul-20 | Aug-20 Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | | | | |
| | | Number I | Klebsiella ca | ses (SBU | HB) | | | | | | Public Health V Dashboard (Ap | /ales: Healthcare oril 2021) | e Acquired |

Measure 1: Rate of Klebsiella spp. Bacteraemia cases per 100,00 of the population Measure 2: Number of Klebsiella spp. bacteraemia cases

How are we doing?

- In 2020/21, there had been 102 cases of *Klebsiella spp.* bacteraemia within the Health Board. This was 24% higher than the number of cases in the previous year. The cumulative cases for 2020/21 was 24 cases above the projected IMTP profile and 30 cases above the Welsh Government infection reduction expectation for the Health Board.
- There were 10 cases of *Klebsiella spp*. bacteraemia in March 2021; this was 5 cases above the IMTP monthly profile and 4 cases above the Welsh Government monthly infection reduction expectation.
- 45% of the cases in 2020/21 were considered community acquired; 55% were considered hospital acquired. Of the latter, 70% were associated with Morriston Hospital, 18% with Singleton Hospital, and 11% with Neath Port Talbot Hospital.
- In March 2021, 1 of the 10 cases was considered hospital acquired; this was associated with Singleton Hospital.
- Of the cumulative cases in 2020/21, 29% were thought to have a urinary source, 16% a hepato-biliary source, and 15% a respiratory source. For hospital acquired infections, 25% of cases were considered to have a respiratory source, 14% a urinary source, and 7% a hepato-biliary source.

What actions are we taking?

- Service Delivery Groups are monitoring staff training in relation to Standard Infection Control Precautions and ANTT training.
- Morriston Service Delivery Group has established a Consultant-led bacteraemia review group. Neath Port Talbot & Singleton Hospital Service Delivery Group is establishing a Service Group IPC Group, plus a Divisional Ward Manager IPC group, which feeds into the main IPC Group, which will monitor Tier 1 hospital acquired infections.

What are the main areas of risk?

- A significant proportion of *Klebsiella spp.* bacteraemia is community acquired, with many patient related contributory factors, particularly in relation to urinary tract infection and biliary tract disease. As such, it will be a challenge to prevent a significant proportion of these.
- Use of pre-emptive beds on acute sites increases risks of infection transmission.
- Bed occupancy, which is frequently close to, or exceeds, 90% is associated with an increased risk of hospital acquired infections.
- Reduction initiatives are compromised by high levels of service activity, staffing vacancies, and reliance on temporary staff.

- The Health Board cumulative incidence of *Klebsiella spp.* bacteraemia per 100,000 population for 2020/21 was 26.20, the third highest incidence in NHS Wales.
- The incidence in March 2021 was 30.24/100,000 population; this was the second highest monthly incidence for the major acute Health Boards in Wales.

| | | | | | | | F | 'seud | omon | as Ae | rugino | osa <i>Ba</i> | acterae. | mia | | | |
|--------------------|---------|----------|--------|--------------------|------------------|--------------------|-------------------|-----------------------------|------------|----------|-----------|---------------|----------|--------------------|--|--|----------------------------------|
| Quadra | ant of | Harm: | H | arm fror | n overw | /helmea | 1 NHS a | and soc | ial care | system | າ. | | | Executive Lead: | | /illiams, Interim Di Patient Experience | |
| Quadru | uple A | im: | | | e Aim 2 | | | | | | | | essible | | | Period: Mar | ch 2021 |
| | | | | ealth an ngagem | d social ent. | care s | ervices, | enable | d by di | gital an | d suppo | orted by | | IMTP Profile | WG Target | Current Status (against profile): | Movement: (12 month trend) |
| Measur | re 1: C | umulativ | ve rat | e of P.a | aerugind | osa bac | teraemi | ia cases | s per 10 | 0,000 | of the po | opulatio | n | N/A | N/A | | ↓ ● |
| Measur | | umber o | | | | | | | | | | | | N/A | N/A | | \downarrow |
| | (1) I | Rate of | Pseu | ldomor | nas aeri | uginos | a bacte | raemia | per 10 | 0,000 | of the p | populat | ion. | | Benc | hmarking | |
| 10 — 5 — 0 — | Mar-20 | Apr-20 | May-20 | 07-un Pseudo | 02-In monas R | 02-6nV Rate per | 02-dəS 100k po | ος c; Ο Ο SBU I | Шо20 В) | Dec-20 | Jan-21 | Feb-21 | Mar-21 | LHB Wales | Cumulative Cases (Apr 20 - Mar-21) 148 | Cumulative Rate (Apr 20 - Mar 21) 4.72 | Rank (Cumulativ Number) |
| | | | -8- | Cumula | tive Pseu | udomon | as Rate | per 100ł | Kpop (Sl | BU HB) | | | | SBU | 19 | 4.88 | 1 |
| | | (2) | Num | ber of | Psuedo | monas | aerua | inosa b | actera | emia c | ases | | | AB | 24 | 4.06 | 4 |
| | | () | | | | | J | | | | | | | BCU | 33 | 4.73 | 6 |
| 6 | | | | | | | | | | | | | | C&V | 29 | 5.84 | 5 |
| 5 — | | | | | | | | | | | | | | CTM | 20 | 4.49 | 2 |
| 4 | | | | 1 | | | | | | | | , | | Hdda | 22 | 5.71 | |
| | Mar-20 | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | | | | |
| | | | | ■ N | lumber F | seudon | nonas ca | ases (SB | U HB) | | | | | | Public Health W Dashboard (Ap | ales: Healthcare A ril 2021) | cquired |

Measure 1: Rate of Pseudomonas aeruginosa Bacteraemia cases per 100,00 of the population Measure 2: Number of Pseudomonas aeruginosa bacteraemia cases

How are we doing?

- In 2020/21, there had been 19 cases of *Pseudomonas aeruginosa* bacteraemia within the Health Board. This was 32% fewer than the number of cases in the previous year. The cumulative cases for 2020/21 was 8 cases below the projected IMTP profile and 2 cases below the Welsh Government infection reduction expectation for the Health Board.
- There was one case of *Pseudomonas aeruginosa* bacteraemia in March 2021; this was community acquired. This was in line with the IMTP monthly profile and the Welsh Government monthly infection reduction expectation.
- 58% of the cases in 2020/21 were considered community acquired; 42% were considered hospital acquired. Of the latter, 75% were associated with Morriston Hospital, and 25% with Singleton Hospital.


What actions are we taking?

- Service Delivery Groups are monitoring staff training in relation to Standard Infection Control Precautions and ANTT training.
- Morriston Service Delivery Group has established a Consultant-led bacteraemia review group. Neath Port Talbot & Singleton Hospital Service Delivery Group is establishing a Service Group IPC Group, plus a Divisional Ward Manager IPC group, which feeds into the main IPC Group, which will monitor Tier 1 hospital acquired infections.

What are the main areas of risk?

- A significant proportion of *Pseudomonas aeruginosa* bacteraemia is community acquired, with many patient related contributory factors. As such, it will be a challenge to prevent a significant proportion of these.
- Bed occupancy, which is frequently close to, or exceeds, 90% is associated with an increased risk of hospital acquired infections.
- Reduction initiatives are compromised by high levels of service activity, staffing vacancies, and reliance on temporary staff.

- The Health Board cumulative incidence of *Pseudomonas aeruginosa* bacteraemia per 100,000 population for 2020/21 was 4.88, the third highest incidence in NHS Wales, although the lowest total number of cases.
- The incidence in March 2021 was 3.02/100,000 population; this was the third lowest monthly incidence for the major acute Health Boards in Wales.



Measure 1: % compliance with Hand Hygiene Audits

How are we doing?

- Average compliance with Hand Hygiene for the Health Board for 2020/21 was 95.95%. Health Board compliance with hand hygiene (HH) for March 2021 was 95.53%.
- Average compliance for all of the Service Delivery Groups for 2020/21 was ≥93%.
- Due to COVID-19, many areas that would report on hand hygiene compliance were not operational during 2021/21.
- For March 2021, 56 wards/units (57%) reported compliance ≥95%.
- Five wards/departments (5%) reported compliance between 90% and 94%; nine wards/units (9%) reported compliance of 89% or below.
- 28 wards/departments had not uploaded the results of their audits undertaken in March 2021 at the time of updating this report.
- Results over time indicate there are challenges to achieving sustained improvements in compliance; however, there are recognised limitations with selfassessment.

What actions are we taking?

- Service Delivery Groups can agree internal peer review audit programmes, undertaking these between wards, specialties or Service Delivery Groups.
- Hand Hygiene Training programme is being delivered.
- Training of ward Hand Hygiene Coaches continues and these continue to deliver approved training at ward level.

What are the main areas of risk?


- Main route of infection transmission is by direct contact, particularly by hands of staff.
- Poor compliance with good hand hygiene practice is likely to result in transmission of infection.
- Current scoring system may be giving an overly assuring picture of compliance; greater validation of the scores needs to be undertaken.
- The Infection Prevention & Control undertakes spot-check Hand Hygiene compliance audits; results generally show good compliance but the impact of the Hawthorne effect is such that results should be viewed with caution.
- The current system and format of scoring fails to highlight particular staff groups with lower compliance rates than others.

How do we compare with our peers?


• The Hand Hygiene score has been removed from the all-Wales dashboard because of the inherent difficulty in using one score to represent a whole Health Board.

| Quadrant of Harm: Harm from overwhelmed NHS and social care system. Executive Lead: Quadruple Aim: Quadruple Aim 4: Wales has a higher value health and social care system that has demonstrated rapid improvement and innovation and enabled by data and focused on outcomes Local Tar Measure 1: % Proportion narrow-spectrum antibiotics prescribed >55% Measure 3: % Stop or review date documented 100% Measure 5: % Prescriptions reviewed within 72 hours 100% Measure 6: Outcome of 72hr review - % Stopped Monitor Measure 9: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 9: Outcome of 72hr review - % Continued unchanged Monitor 100% % compliance with Antimicrobial Audits 100% 40% 40% 20% Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 (1) Proportia entibiotic (1) Provente - % (5) % prescriptions reviewed within hours (6) Outcome of 72hr review - % (5) % prescriptions nervewed within hours (6) % prescriptions nervewed within hours (2) % indication for antibiotic (2) % indication for antibiotic prescribed (2) % indication for antibiotic prescribed (2) % indication for antibiotic (6) % prescriptions reviewed within hours (6) % prescriptions | | Christ | | | | |
|--|-----|--|-------------|-------|--|---------|
| that has demonstrated rapid improvement and innovation and enabled by data and focused on outcomes Local Tar Measure 1: % Proportion narrow-spectrum antibiotics prescribed >55% Measure 2: % Indication for antibiotic documented 100% Measure 3: % Stop or review date documented 100% Measure 4: % Appropriate antibiotic prescriptions choice 100% Measure 5: % Prescriptions reviewed within 72 hours 100% Measure 7: Outcome of 72hr review - % Stopped Monitor Measure 8: Outcome of 72hr review - % Witched to Oral Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor 100% \$ Monitor 80% \$ \$ 60% \$ \$ 40% \$ \$ 20% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 100% \$ \$ 100% \$ \$ 0% \$ \$ 001 \$ \$ | | Christine Williams, Interim Director of Nursing & Patient Experience | | | | |
| data and focused on outcomes Local 1 ar Measure 1: % Proportion narrow-spectrum antibiotics prescribed >55% Measure 2: % Indication for antibiotic documented 100% Measure 3: % Stop or review date documented 100% Measure 4: % Appropriate antibiotic prescriptions choice 100% Measure 5: % Prescriptions reviewed within 72 hours 100% Measure 6: Outcome of 72hr review - % Stopped Monitor Measure 8: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 9: Outcome of 72hr review - Switched to Oral Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor 100% \$ Compliance with Antimicrobial Audits 100% \$ \$ 0% \$ \$ 00% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% | | | arch 2021 | | | |
| Measure 2: % Indication for antibiotic documented 100% Measure 3: % Stop or review date documented 100% Measure 4: % Appropriate antibiotic prescriptions choice 100% Measure 5: % Prescriptions reviewed within 72 hours 100% Measure 6: Outcome of 72hr review - % Stopped Monitor Measure 7: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 8: Outcome of 72hr review - % Continued unchanged Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits Monitor 100% % Monitor 0% Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 0% Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 | jet | Current Status (against target): | | | Movement: (Quarter on quarte | |
| Measure 2: % Indication for antibiotic documented 100% Measure 3: % Stop or review date documented 100% Measure 4: % Appropriate antibiotic prescriptions choice 100% Measure 5: % Prescriptions reviewed within 72 hours 100% Measure 6: Outcome of 72hr review - % Stopped Monitor Measure 7: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 8: Outcome of 72hr review - % Continued unchanged Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits Monitor 100% % Monitor 0% Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 0% Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 | | | ✓ | | ↓ (| |
| Measure 3: % Stop or review date documented 100% Measure 4: % Appropriate antibiotic prescriptions choice 100% Measure 5: % Prescriptions reviewed within 72 hours 100% Measure 6: Outcome of 72hr review - % Stopped Monitor Measure 7: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 8: Outcome of 72hr review - % Switched to Oral Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits 100% 100% \$ (1) Proportion narrow-spectrum antibiotic prescribed 100% \$ (2) % indication for antibiotic documented 100% \$ (3) % stop or review date document (4) % appropriate antibiotic (3) % stop or review date document (4) % appropriate antibiotic (5) % prescriptions reviewed within hours (6) Outcome of 72hr review - % \$ (6) Outcome of 72hr review - % \$ | | | X | | 1 | |
| Measure 4: % Appropriate antibiotic prescriptions choice 100% Measure 5: % Prescriptions reviewed within 72 hours 100% Measure 6: Outcome of 72hr review - % Stopped Monitor Measure 7: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 8: Outcome of 72hr review - Switched to Oral Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits Monitor 100% \$ \$ 100% \$ \$ 100% \$ \$ 100% \$ \$ 100% \$ \$ 100% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ \$ 0% \$ | | | X | | ↓ (| |
| Measure 5: % Prescriptions reviewed within 72 hours 100% Measure 6: Outcome of 72hr review - % Stopped Monitor Measure 7: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 8: Outcome of 72hr review - Switched to Oral Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits Monitor 100% * (1) Proportion narrow-spectrum antibiotics prescribed 60% * (2) % indication for antibiotic documented 40% * (3) % stop or review date document (4) % appropriate antibiotic prescriptions reviewed within fours (6) Outcome of 72hr review - % Stopped | | | X | | 1 | |
| Measure 6: Outcome of 72hr review - % Stopped Monitor Measure 7: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 8: Outcome of 72hr review - Switched to Oral Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits 100% \$ 80% \$ 60% \$ 40% \$ 20% \$ Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 Q3 20-21 Q4 20-21 \$ 600 \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ \$ \$ 0% \$ | | | × | | 1 | |
| Measure 7: Outcome of 72hr review - % Changed (escalated or de-escalated) Monitor Measure 8: Outcome of 72hr review - Switched to Oral Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits Monitor 100% | | | | | | |
| Measure 8: Outcome of 72hr review - Switched to Oral Monitor Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits 100% (1) Proportion narrow-spectrum antibiotics prescribed 60% (2) % indication for antibiotic documented 40% (3) % stop or review date document 0% (1) Proportion serviewed within hours 0% (3) % stop or review date document (4) % appropriate antibiotic prescriptions reviewed within hours (6) Outcome of 72hr review - % Stopped | | | | | | |
| Measure 9: Outcome of 72hr review - Continued unchanged Monitor % compliance with Antimicrobial Audits 100% 80% 60% 40% 20% Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 | | | | | | |
| 100% Q4 20-21 100% Q4 20-21 80% Q4 20-21 60% Q1 20-21 Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 | | | | | | |
| 60% (2) % indication for antibiotic documented 40% (3) % stop or review date document 20% (4) % appropriate antibiotic prescriptions choice 0% (5) % prescriptions reviewed within hours (6) Outcome of 72hr review - % Stopped | | 63.0% | 66.0% | 62.0% | - | 61.0% |
| 80% Image: Constraint of the second seco | M | Iorristor | n Singleton | NPTH | MH & LD | HB Tota |
| 40% 20% 0% Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 (3) % stop or review date document (4) % appropriate antibiotic prescriptions choice (5) % prescriptions reviewed within hours (6) Outcome of 72hr review - % Stopped | | 93.0% | 93.0% | 83.0% | 100.0% | 92.1% |
| 40% 20% 0% Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 (4) % appropriate antibiotic prescriptions choice (5) % prescriptions reviewed within hours (6) Outcome of 72hr review - % Stopped | d | 81.0% | 87.0% | 97.0% | 100.0% | 84.8% |
| 20% 0% Q1 20-21 Q2 20-21 Q3 20-21 Q3 20-21 Q3 20-21 Q4 20-21 Q5 % prescriptions reviewed within hours (6) Outcome of 72hr review - % Stopped | | 96.0% | 97.0% | 95.0% | | 96.0% |
| Q1 20-21 Q2 20-21 Q3 20-21 Q4 20-21 (6) Outcome of 72hr review - % Stopped | 72 | 94.0% | 86.0% | 86.0% | 67.0% | 91.5% |
| (7) Outcome of 72hr review 1/4 | | 16.0% | 25.0% | 14.0% | 0.0% | 17.2% |
| Measure 1 Measure 2 Measure 3 Changed (escalated or de-escalated | | 12.0% | 4.0% | 5.0% | 0.0% | 10.6% |
| → Measure 4 → Measure 5 → Measure 6 (8) Outcome of 72hr review - Switch → Measure 7 → Measure 8 → Measure 9 to Oral | d | 4.0% | 2.0% | 5.0% | - | 5.8% |
| (9) Outcome of 72hr review - Continued unchanged | | 68.0% | 69.0% | 77.0% | 100.0% | 66.4% |


| Aleasure 1: % Proportion narrow-spectrum antibiotics prescribed | Measure 8: Outcome of 72hr review - Switched to Oral |
|--|--|
| <i><u>Aeasure 2</u>: % Indication for antibiotic documented on chart</i> | Measure 9: Outcome of 72hr review - Continued unchanged |
| <u>Measure 3</u> : % Stop or review date documented | |
| <u>Measure 4</u> : % Appropriate antibiotic prescriptions choice | |
| <u>Aeasure 5</u> : % Prescriptions reviewed within 72 hours | |
| <u>Aeasure 6</u> : Outcome of 72hr review - % Stopped | |
| <u>Measure 7: Outcome of 72hr review - % Changed (escalated or de-escalated or d</u> | scalated) |
| How are we doing? Proportion of narrow-spectrum antibiotics used is above target ac | |
| Good compliance is achieved across most of the measures, howe | ever improvements in the consistency of review at 72 hours is needed within many of the |
| The e-prescribing system in Neath, has led to a reduction in the n other sites. | number of indications recorded but an increase in stop/review dates when compared to the |
| At the 72 hour review, a large proportion of prescriptions are cont | inued unchanged with low rates of IV to oral switch. |
| Vhat actions are we taking? | |
| | tibiotic Review Kit) 72 hour mandatory review into Neath and Singleton. for all electronic aper charts, all antibiotic prescriptions will suspend at 72 hours and will require a review by |
| | Improvement Projects focusing on the measures included above. These projects will be run tor and introduce interventions within their own speciality in order to improve antibiotic |
| | |
| Vhat are the main areas of risk? | |
| Lack of consistent review of all antibiotic prescriptions by 72 hours | 8 |
| Lack of review of IV antibiotics | |
| | |
| low do we compare with our peers? | |
| Proportion of narrow-spectrum antibiotics is above the Welsh aver | rage for the acute sites in Wales |
| All other measures are above the Welsh average with the exception | |



| Measure 1: Number of new Never Events |
|--|
| Measure 2: Number of new Serious Incidents (SI's) |
| Measure 3: % Serious Incidents Assured Within The Agreed Timescales |
| |
| How are we doing? |
| SI Scorecard – completed on 27 April 2021. |
| Total number of incidents reported in March 2021 was 1,802. This compares to 1,552 reported in March 2020. 3 Serious Incidents (SI's) were reported to Welsh Government (WG) in March 2021. Of the 3 new serious incidents reported to WG in March, 1 was an unexpected death in Mental Health (MH) and 2 were patient falls. In terms of severity of incidents, there were 6 incidents (0.3%) resulting in severe harm and 18 deaths recorded for the month of March. The Health Board's target for incidents resulting in severe harm is 0.5% of the total number of incidents reported. No Never Events were reported for the month of March 2021. |
| What actions are we taking? |
| SI consequence training being undertaken with representatives from each Service Group – commenced April 2021. |
| Serious Incident training being delivered to Service Groups commencing September 2021. |
| Weekly/Monthly meetings with each Service Group to review historical SI's and focus on getting these closed. |
| • Weekly Monthly meetings with each bervice Group to review historical or s and focus on getting these closed. |
| |
| |
| |
| |
| |
| What are the main areas of risk? |
| Maintaining 80% target closure date whilst ensuring quality of investigation reports and robust learning from the incidents. Number of open MH incidents requiring closure. |
| How do we compare with our peers? |
| Comparison data from peer organisations not available |



| | easure 1: Total Number of pressure ulcers acquired in hospital |
|----|---|
| | asure 2: Number of grade 3, 4 and unstageable pressure ulcers acquired in hospital |
| Но | w are we doing? |
| • | The measure for pressure ulcers is displayed as the number of pressure ulcers acquired in hospital. There has been an increase in the rate of pressure ulcer development for in-patients since November 2020 to December with an increase from 42 to 61. The |
| | reports in January 2021 did then decrease to 51 and then further to 48 in Feb 2021 |
| | The number of pressure ulcers in comparison to February 2020 has increased from 41 to 48 in Feb 2021. |
| | The number of pressure ulcers reported between Feb 2020 and July 2020 were on average reducing and have increased between August 2020 and Dec |
| | 2020, and are since reducing. |
| | The number of Deep pressure ulcers have reduced slightly since November 2020 from 4 to 3 in December 2020, 2 in January 2021 and slight increase to 3 in February 2021. |
| | 8 Device related pressure ulcers were reported between December 2020 and February 20201 |
| | The increase in pressure ulcers over the winter period corresponds with the surge in demand for unscheduled in-patient care. |
| ۷ŀ | nat actions are we taking? |
| | Pressure ulcer risk assessment training and education for the All-Wales Risk Assessment PURPOSE T was rolled out by practice educators and Tissue |
| | Viability Nurses (TVN's) to registered nurses across all in-patient areas of the Health Board. Purpose T has now been rolled out across all acute sites and |
| | replaced Waterlow risk assessment in compliance with All Wales Documentation. |
| | Ongoing training via the e-learning training package by NWIS in collaboration with All Wales TVN's is available for all NHS staff via ESR and for non-health |
| | board staff through e-learning@Wales. The TVNs are also providing training face to face. |
| | The PURPOSE T risk assessment is included in the new Swansea Bay Risk Assessment booklet and single assessment sheets are available for re- |
| | assessments |
| • | The Pressure Ulcer Prevention Strategic Group (PUPSG) continue meet quarterly with a multi-disciplinary membership and representation from all Service |
| | Delivery Unit's (SDU's), the Executive team and Welsh Risk Pool. The next PUPSG meeting is to be held on 17 th May 2021. |
| • | Each SDU submits a quarterly report to PUPSG containing an analysis of local pressure ulcer causal factors presented in a heat map. |
| , | Work streams for each SDU are aligned to their pressure ulcer causal factor heat map, ensuring that the work streams apply resources to mitigate the risk of |
| | repeat events causing avoidable pressure ulcers. |
| • | Each SDU continue to work on their Strategic Quality Improvement Plan (SQuIP) for pressure ulcer prevention. They continue to develop new work streams |
| | based on the heat mat for their area, and close those that have been implemented. The SQuIP creates a single source of information for each Service |
| | Delivery Unit in respect of Pressure Ulcer Prevention and will facilitate the escalation and monitoring of work in relation to prevention. |
| | Peer review scrutiny panels are held in each hospital to identify causal factors for pressure ulcer development, develop work streams and to ensure the |
| | information regarding the type of injury and grade of pressure ulcer recorded in Datix is correct. These are now managed by individual directorates. |
| | The Datix data for this report has been collated and reported one month in arrears as previously detailed, to ensure timely peer review scrutiny is completed |
| | and any relevant changes to the Datix incident actioned. The pressure ulcer data will continue to be presented one month in arrears |
| ۷r | hat are the main areas of risk? |
| • | There remains a reliance on using bank and agency staff where there is a shortfall in the required staffing levels, due to the impact of COVID-19 and |
| | vacancies |
| | Staff that are not trained on PURPOSE T risk assessment which has replaced Waterlow as the risk assessment tool. |
| | w do we compare with our peers? |
| , | Benchmarking data not available. |



Measure 1: Total Number of pressure ulcers acquired in the community.

Measure 2: Number of grade 3, 4 and un-stageable pressure ulcers acquired in the community

How are we doing?

- There has been a slight decrease in pressure ulcer development in the community during the months of December 2020, January and February 2021
- The number of pressure ulcers decreased from 29 in Nov to 26 in December 2020. With slight reduction to 25 in January 2021 and 24 in Feb 2021
- There has been a slight increase in the number of deep pressure ulcers, that is, Grade 3, 4 and Unstagable occurring in the community, between Nov 2020 and December 2021 by 2. There has since been a decrease between December 2020 and Jan 2021 and a further decrease between Jan 2021 and Feb 2021 when 4 Deep pressure ulcers have been reported.
- Compared to February 2020 when 8 deep pressure ulcers were reported, the number of deep pressure ulcers is 50% less than Feb 2020. The average over the year was 6.2, with 4 being the least amount of Deep pressure ulcers developed in 1 month. 11 being the highest in the month of Oct 2020.
- 4 Device related Pressure ulcers were reported between December 2020 and Febuary 2021.

What actions are we taking?


- The Pressure Ulcer Prevention Strategic Group (PUPSG) meet quarterly with a multi-disciplinary membership and representation from all Service Delivery Unit's (SDU's), the Executive team and Welsh Risk Pool.
- A quarterly report is submitted to PUPSG from each SDU. The report contains analysis of local pressure ulcer causal factors presented in a heat map. The heat map presents a visual analysis, using colour, to convey causal factor data.
- Work streams for each SDU are aligned to their pressure ulcer causal factor heat map, ensuring that the work streams apply resources to mitigate the risk of repeat events causing avoidable pressure ulcers.
- Each SDU continues to update their Strategic Quality Improvement Plan (SQuIP) for pressure ulcer prevention. The SQuIP creates a single source of
 information for each Service Delivery Unit in respect of Pressure Ulcer Prevention and will facilitate the escalation and monitoring of work in relation to
 prevention.
- Ongoing work with closing work streams on the SQUIP and the development of new work streams are ongoing to ensure their objectives are achieved & causal factor risks are managed effectively
- Peer review scrutiny panels are held in each locality to identify causal factors for pressure ulcer development, develop work streams and to ensure the information regarding the type of injury and grade of pressure ulcer recorded in Datix is correct.
- Education continues to be provided to staff by Tissue Viability Nurses (TVN's) and PUPIS.
- The implementation of Purpose T All Wales Risk Assessment has been rolled out in the Acute hospitals in Swansea Bay university Health Board (SBUHB) and is now being rolled out in the community. Community staff have access to the e-learning package developed by NWIS in collaboration with the All Wales TVNs and Education sessions are being delivered face to face by the Lead TVN and the community TVNs.
- The Datix data for has been collated and reported one month in arrears as previously detailed, to ensure timely peer review scrutiny is completed and any relevant changes to the Datix incident actioned. The pressure ulcer data will continue to be presented one month in arrears

What are the main areas of risk?

The Primary Care & Community Services Delivery Unit are supporting large numbers of frail older people at home who are at increased risk of developing pressure damage.

How do we compare with our peers?

• No benchmark data available.



Appendix 1- Integrated Performance Report

Measure 1: Total Number of Inpatient Falls Measure 2: Falls per 1,000 bed days

How are we doing?

December 2018 shows 226 falls, December 2019 has 297 falls overall. March 2020 shows a total of 220 falls with an increase in November & December to 247. This reduced to 171 falls in March 2021. November & December was at the height of the 2nd COVID-19 wave.

- Looking at the number of falls between March 2020 & March 2021:
 - Morriston recorded its lowest number in June where there were 52 falls and 129 at its highest in December 2020.
 - Singleton recorded its lowest number in October at 28 falls and its highest at 48 in September & December
 - NPT recorded its lowest number at 28 in March 21 and its highest in March 20 as 56
 - MH /LD recorded its lowest number at 22 in March 21 and its highest at 71 in August 20

What actions are we taking?


- The strategic falls group (HFIPSG) reconvened in March 2021 and continued work on development of a causal factor matrix and working with Welsh Risk Pool. The aim being to provide standardised investigative tools which will be available within DATIX as part of the strategic improvement plan.
- The group have requested that a sub-group develop an investigation tool to support a Hot debrief following a fall.
- Delivery Group Scrutiny panels are in place and updates provided to the strategic group to support sharing & learning.
- Learning and reflections from falls management during COVID-19 was discussed as part of the March agenda.

What are the main areas of risk?

- The Health Board (HB) continues to develop the Hospital Falls Inpatient Strategic Group
- Further Develop the standardisation of investigation Tools.

How do we compare with our peers?

- The Health Board (HB) policy includes the recommended guidance from NICE and the recommendations from the 2017 National inpatient Falls Audit, which is in line with the all-Wales approach.
- The Health board will roll out the All Wales Datix system.



Measure 1: % Universal Mortality Reviews (UMR) undertaken within 28 days of death. Measure 2: % Stage 2 Review forms completed.

How are we doing?

- Welsh Government Mortality Review Performance Swansea Bay University Health Board (SBU HB) achieved 100% completion of Universal Mortality Reviews (UMRs) within 28 days of death in February 2021
- The Health Board UMR rate reported in February 2021 was 100%.
- Completion of Stage 2 reviews for December 2020 deaths was at 75%.
- Mental Health and Community data remains unavailable via the eMRA application at present. This is being addressed by Informatics.

What actions are we taking?


- Escalation process for missing stage 2 reviews confirmed with Morriston Unit Medical Director to improve completion rates.
- In Medicine, all the Stage 2 reviews to be discussed bi-monthly at their audit meetings.
- Mental Health & Learning Disabilities (MH&LD) report that all inpatient deaths in the Delivery Unit are Stage 1 reviewed at time of death and are allocated by the QI team as necessary to consultants for Stage 2 review. The outcomes are presented initially to the Serious Incident Group and then to the Quality & Safety Committee. Older Persons Mental Health Services also hold quarterly Mortality Review meetings to discuss findings. A modified Stage 1 form introduced in Jan 2018 allows for identification of patients who have a mental health, dementia or learning disability diagnosis across the Health Board.

What are the main areas of risk?


- Timeliness of Stage 2 completion.
- Implementation of the Medical Examiner role is accompanied by risk of increased numbers of 'Stage 2' reviews required: the Medical Examiner role will effectively deliver Stage 1 reviews. It is recognised that phased implementation and as yet uncertain recruitment means that the impact will be similarly phased.
- A number of IT issues continue with eMRA.

How do we compare with our peers?

• SBU HB remains the top ranking Health Board for the percentage of stage one mortality reviews undertaken within 28 days of death.



| Μ | leasure 1: Crude hospital mortality rate (less than 75 years of age) |
|---|---|
| H | ow are we doing? |
| • | The Swansea Bay University Health Board (SBU HB) Crude Mortality Rate for under 75s in the 12 months to February 2021 was 1.17%, compared with 0.78% for the same period last year. |
| • | The graphs demonstrate a rolling 12 month position. Whilst there has been an increase in the overall mortality rate, there were less deaths in this age group between March 2020 and February 2021 compared with March 2019 and February 2020. The primary driver for the increase in the rate is less admissions in the most recent time period. |
| • | Site level performance is as follows: (previous year in brackets) Morriston 2.05% (1.30%), Neath Port Talbot 0.18% (0.16%), Singleton 0.57% (0.43%). Site comparison is not possible due to different service models being in place. |
| • | There were 60 in-hospital Deaths in this age group in February 2021 and 67 in February 2020: Morriston 41 (39), Neath Port Talbot Hospital 0 (4), and Singleton 18 (23). |
| • | The number of deaths for Surgical and Elective cases remains consistently low for this age group. |
| | |
| W | /hat actions are we taking? |
| • | All Unit Medical Directors have access to the Mortality Dashboard to enable them to review mortality data and mortality review performance and learning. |
| • | Reporting and assurance arrangements for mortality review performance and learning will be reviewed by the Executive Medical Director. |
| | |
| W | /hat are the main areas of risk? |
| • | There is a risk of harm going undetected resulting in lessons not being learned. Our approach is designed to mitigate this risk and ensure effective monitoring, learning and assurance mechanisms are in place. |
| H | ow do we compare with our peers? |
| • | SB UHB are below the all-Wales Mortality rate for the 12 months to February 2021 – 1.17% compared with 1.24%. |



Source: Nursing Care Metrics (April 2021)

Measure 1: % patients with completed NEWS score and appropriate responses actioned

How are we doing?

- The overall Health Board (HB) performance is good, but we need to understand why the compliance at Morriston has dropped.
- The Recognising Acute Deterioration and Resuscitation (RADAR) group will continue to monitor NEWS and responses.

What actions are we taking?


- Delivery Unit Quality & Safety groups continue to regularly review the percentage of patients with a completed NEWS score.
- The RADAR Group agreed a Deterioration Dashboard for monitoring clinical areas response to acute deterioration. The Dashboard includes; sepsis, AKI, outreach activity, cardiac arrest/2222 calls and training compliance for ILS. The data was intended to provide an overview of how the HB monitors acute deterioration and offer the opportunity for greater scrutiny as required. The dashboard was populated quarterly, data collection ceased during COVID.
- There no funding for the Sepsis programmes in the HB. Data reporting to Welsh Government has stopped. The annual plan for 21/22 included aims to secure funding for an RRAILS improvement lead and sepsis lead posts
- The Chair of the RADAR group, Dr A Macnab, is in discussion with the AKI steering group and has suggested they become a single entity.
- The new NEWSCymru chart has been rolled out across the Health board. Early indication show a significant improvement in accuracy as expected from the pilot.
- Following the successful deployment of new defibrillators at Morriston & NPT, the planned upgrade at Singleton has now also been completed.
- No updates received from Unit Medical Directors.

What are the main areas of risk?

• Suboptimal data collection and submission of sepsis screening and management.

How do we compare with our peers?

• The many aspects of the work of the RADAR group has placed Swansea Bay HB ahead of our peers. However, we are still unable to collect and report on key areas such as sepsis.



Measure 1: % episodes clinically coded within one month post episode end date

How are we doing?

- For February the team exceeded the 95% clinical coding completeness Welsh Government (WG) target achieving 96% within 30 days.
- The completeness within 30 days for 2020/21 (snapshot position) was April 94%, May 97%, June 97%, July 96%, August 96%, September 96%, October 95%, November 93%, December 93%, January 95% and February 96%.
- The cumulative coding completeness for 2020/21 financial year is so far, April 99%, May 99%, June 99%, July 99%, August 99%, September 99%, October 99%, November 99%, December 99% and January 98%.

What actions are we taking?


- Review of roles and responsibilities in the department to ensure that communication and working processes continue at optimum levels.
- Overtime undertaken by coding staff to support the overall performance and effectiveness of the clinical coding service.
- Daily coding performance updates for all sites.
- Investigating ways of increasing electronic sources for coding.

What are the main areas of risk?

- Availability of the Health Records in a timely manner, however joint working and support is addressing and mitigating this risk currently.
- Missing clinical information in medical notes, notes are sent back to wards for amalgamation of the clinical information.

How do we compare with our peers?

• The indicator above is now showing performance against the new target introduced of 95% within 30 days target. Swansea Bay University Health Board's (SBUHB) national reported performance in February was 95%. SBUHB is one of the top performing Health Boards.



Measure 1: % of completed discharge summaries

How are we doing?

- Performance has been within control limits over the last 6 months, with the majority of discharge notifications being completed at all sites
- The dashboard shows overall Health Board (HB) performance in March 2021 was 65% of discharges ever completed
- However, the dashboard from which the above data is taken has been shown to be inaccurate, and requires manual correction by managers, and the completion rates are significantly higher after correction
- Issues raised
 - Discharge Summary Software do not align with Swansea Bay UHB clinical processes that reflect transfers between hospitals, regional specialities etc
 - For example:
 - When transferring patients between hospital sites, the software prevents completion of a discharge summary from the donor hospital
 - Where a regional speciality chooses to use the software for brief procedures (e.g. dressing change), and a patient has a series of multiple daily treatments, the software prevents completion of a discharge summary from any previous attendance
 - Discharge Summary software does not display when pharmacist has not yet completed their actions
 - The Discharge Summary software interprets the default consultant as the one attributed on admission, rather than the one the care was delivered under Dashboard
 - \circ Dashboard
 - Is not live, so any summaries completed are not reflected for 24 hours
 - Dashboard inaccuracies mean that the list of outstanding summaries does not reflect the actual caseload for doctors to work on

What actions are we taking?

- The Executive Medical Director (MD) has asked a Deputy Medical director to oversee a relaunch of the programme of work to improve Electronic Transfer of Notification (ETOC) performance.
- A task and finish group, including the CCIO, Digital Team, service managers and AMD has been created to lead the development of solutions. It reports into the Monthly Clinical Outcomes and Effectiveness Group
- Digital Team are amending the Discharge Summaries Dashboard to identify those that are signed off by pharmacy and those that are not. Implementation is to be monitored via the task and finish group.
- Doctors in Training will be granted permission by the Digital Team to change the consultant on the discharge summary if incorrectly recorded
- The refresh rate of the dashboard will be made as often as the system allows
- Senior clinicians to hold discussions with those specialities regarding moving to alternatives to discharge summary software if the patients aren't strictly admitted
- Monitoring of Discharge Summary Completion performance is monitored and discussed at the following meetings, with actions recorded
 - o Monthly exec MDs and Service Group Medical Directors meetings
 - o Weekly Morriston Clinical Cabinet Meetings
 - o Singleton/NPTH Clinical leadership meetings
 - o Mental Health & LD Clinical Leadership meetings
 - o Discharge summary completion performance is a mandatory agenda item at monthly departmental governance meetings.


What are the main areas of risk?

- Risk to patient care and the need for readmission.
- The national software solution has incomplete functionality. A change request has been submitted to NWIS to support improvements in its developments.

• The General Medical Practitioner Indemnity Scheme, starting 1st April 2019, which will make the Health Board the defendant in all GP negligence cases, will provide a sharp focus on the quality and quantity of information that is being shared with GP colleagues and their teams.

How do we compare with our peers?

• Swansea Bay University Health Board is the only health board to publish its performance.



Measure 1: % staff (medical & non-medical) undertaking performance appraisals

How are we doing?

Medical: Appraisal rate for the rolling period to March 2021 is 33% not including any exceptional circumstances. Due to COVID-19 and the Chief Medical Officer giving doctors the option for an 'Approved Missed' appraisal in 2020 the appraisal rates have dropped. Percentages are based on 1095 'connected' doctors: Primary 357, secondary 738. The number of prescribed doctors has increased since 2019/20.

Non- Medical: Evidence from reporting figures demonstrates a decrease in PADR compliance from March 2020 71.86% - March 2021 53.14%. This has, in the main, been a result of the Covid 19 pandemic. From the 5 Service Delivery Units (SDUs) and Estates and Ancillary: Mental Health & Learning Disabilities (MHLD) 72.76% a slight decrease of 0.6% on the result of Mar 2020, Morriston 36.25% a decrease of 33.32%, NPT 59.30% a decrease of 14.75%, PCC 82.92% an increase of 6.90%, Singleton 64.01% a decrease of 7.68%, Estates and Ancillary 22.85% a decrease of 50.90%

What actions are we taking?

Medical: Engagement in annual appraisal continued for some doctors in secondary care during 2020 but this was optional. Appraisal engagement has now recommenced for both primary and secondary care. Refresher training for the MARS online system has been offered within secondary care. GP Appraisal Coordinators and Medical Appraisal Leads will be involved in guarterly exception management process, providing doctors with training and advice. Ongoing enhancements to MARS (Medical Appraisal and Revalidation System), appraisers are kept up to date with changes, training provided at local and regional levels, and quality assurance training for appraisers and review of appraisal summaries. Continuing to improve local processes to ensure robust systems are in place. Appraisal data manually entered onto ESR for appraisals completed on MARS for secondary care doctors. There will be a separate graph included to identify data reported directly from MARS.

Non-Medical: To give context to the significant decrease in PADR compliance rate, it was because of Covid 19 that all training was postponed. Moreover, focus and priority on completing PADR's, throughout the pandemic, was paused. This was also seen, with the postponement of introducing the Pay Progression Policy in April 2020. As of April 2021, the Pay Progression Policy remains on hold until further notice.

• We are waiting for further notice regarding the Pay Progression Policy as to when we can release the updates PADR Policy, which was signed off in principle in Feb 2021. • PADR training will resume in June of this year. Dates and times have been planned for the remainder of 2021, with additional dates being planned for 2022. • PADR training will be offered as part of the Managers Pathway as well as open access workshops. • With the significant decrease in compliance with Estates and Ancillary, support and guidance has been offered from Learning & OD. Plans of how to regain increased levels of compliance has been requested by the WOD Committee. •With regards to the last reported actions, because of Covid 19, there has been no further updates as to what or if anything has happened.


What are the main areas of risk?

Medical: Doctors falling behind on appraisal timescales for revalidation: stress for doctor; diversion of doctor's and management time/resource; potential delayed revalidation; ultimately, consequences for licence to practise if failure to engage. Poor quality appraisals - lack of personal/service development and progression; continuation of sub-optimal practices; resistance to change. Ensuring new starters and ad hoc doctors are engaged with the annual appraisal process. Misunderstanding the requirement of Whole Practice Appraisal (WPA) and not including all elements of work undertaken using their GMC licence within their annual appraisals.

Non-Medical: • Covid 19 and its impact on rolling out PADR training • The pace of recovery and expected improvements in compliance rates V recovery from Covid 19/ pandemic fatigue. • Timings of PADR aligning with increment date and in accordance with Pay Progression Guidelines. • Dependence on roll out of Supervisor self-service for PADR Reporting data accuracy, double reporting, use of ESR, accuracy of ESR, IT skills of staff. •Time and resource to complete PADR's - risk around the quality of PADR versus the target figures. •Local administrators and locally held data – change of culture and the time scales to do this. • NHS pay scales/ increment linked to PADR. • Perception of the paperwork being too onerous and therefore not enough time to complete PADR's

How do we compare with our peers?

Medical: National figures not available. Due to COVID-19 p, figures across all Health Boards will be low for appraisal which WG and GMC are aware of. Non-Medical: As of Oct 2020 SBU are behind the National average of 61%. Only CTMUHB and CVUHB are behind with compliance rates of 53.22% and 40.40% respectively. All other large HB's are above the National average with BCUHB having the highest compliance of 73.77%. However, it can be seen from the National results that all the large HB's have experienced decreases in compliance rates as a result of Covid 19.



Appendix 1- Integrated Performance Report

Measure 1: % compliance for the completed level 1 Information Governance (Wales) training element of the Core Skills and Training Framework Measure 2: % compliance for all completed Level 1 competencies within the Core Skills and Training Framework

How are we doing?

Information Governance: The current compliance for Information Governance (IG) Level 1 training is 79% (31st March 2021). The IG Department has produced a training video that staff can access to undertake their mandatory Information Governance training. The video can be used as an alternative to the e-learning package available via the ESR portal. There is also continued IG compliance monitoring by a dedicated IG Training Lead and awareness raising via the Information Governance Group Leads, bulletins, IG intranet pages, and IG Audits.

<u>All Level 1 Competencies:</u> The current level of compliance for Mandatory and Statutory (M&S) stands at 80.89% (March 2021). This is an improvement on the last reported compliance (79.60% in December 2019.) Since then we have had Covid 19, which has had a huge impact on the work of the Health Board (HB) and the focus of the staff. Nonetheless, it can be seen from the current level of compliance, that there has been a concerted effort to remain on top of M&S training across the board. With the ability to work from home as well as those who have had to shield, staff have had the opportunity to work in a more agile manner, which may have given them the ability to spend time in completing necessary training.

What actions are we taking?

Information Governance Continue to send compliance lists for IG Training compliance to directorates and Service Delivery Units.

Continue to report IG training compliance formally to the Information Governance Group and to Audit Committee, as well as include it in the annual public facing SIRO Report. The IG training video has been widely distributed. It is now available in English and Welsh, both on the HB Intranet and published on YouTube. <u>All Level 1 Competencies</u> As a result of the Covid 19 response, much of the actions that were in place in December 2019, remain the same.

Ongoing support through e-learning workshops are not currently in place due to Covid restrictions. However, 1-2-1 assistance is being provided when needed. Investigate Inter Authority Transfer Process to ensure records transfer with employees.

Update outstanding individual records from Action Point. Use additional resources such as apprentices to reduce the backlog on Action Point.

Investigate where compliance in higher level training mitigates the need for level 1 training and implement automatic sign off of competencies.

A review of the Mandatory Training framework is currently being undertaken with all relevant Subject Matter Experts examining the current Mandatory Training Framework to ensure it is fit for purpose and to comment on any changes required.

A further meeting is being organised to meet to discuss the feedback to maximise the recording of Mandatory training delivered via face to face classroom based workshops and to examine alternative ways of recording compliance. However, due to Covid 19, face to face/ classroom based workshops are not happening and will not be happening for the foreseeable future.

What are the main areas of risk?

<u>All level 1 Competencies</u> Lack of resources (highlighted at Audit Committee)

ESR self-service and supervisor self-service roll out and usage.

IT infrastructures and lack of computer literacy amongst staff. Time and access to computers for community based staff


Potential changes to pay progression and increments, when they are enforced post the Covid 19 response.

Retire & Returning employees recruited via Direct Hire processes require manual update of training records if available

Not being able to meet in a Face to Face workshop, where hands-on assistance can be provided.

How do we compare with our peers?

<u>All Level 1 Competencies</u> At the time of writing this report the latest All Wales benchmarking available was October 20. Results for SBUHB show the compliance for the 10 core skills Mandatory Training Framework is slightly above the National average. There are only four other HB's that show a higher compliance rate than SBUHB, these are; PHW, PTLHB, HDUHB & BCUHB.



Measure 1: % workforce sickness absence (Rolling 12 months) Measure 2: % workforce sickness absence (In-month)

How are we doing?

Rolling 12 month performance: Feb 20 – Jan 21 = 7.51%, Mar 20 - Feb 21 = 7.50%, Mar 19 – Feb 20 = 6.16%.

In Month performance: Jan 21 = 8.05%, Feb 21 = 6.41% (was 6.42% in Feb 20) In month performance in Feb 21 saw an improvement of 1.64% on the previous month to 6.41%. In month decrease in sickness was mainly due to a reduction in Covid19 related absence which reduced by 1.13% to 1.20%. Short-term absence (STA) reduced by 0.53%, compared to the previous month, to 2.07%. Long-term absence (LTA) reduced by 1.10% to 4.34%. All service groups saw in month performance improve in Feb 21 compared to Jan 21. Whilst three saw an improvement in their 12-month rolling performance. Highest reason for absence in Feb 21 was stress related absence accounting for 34.3% of absence in Feb 21, an increase of 3.31% on the previous month. If we see a similar pattern of stress related absence as we did after the first wave of Covid19 we are likely to see a further increase in this absence reason in the next few months.

What actions are we taking?

The Covid 19 pandemic has meant that much of our operational HR resources being utilised in different ways, meaning that focus was diverted away from providing support to "normal" activity such as sickness management support. Resources were diverted into areas supporting Covid recruitment and on-boarding activity and workforce planning activities to support the response to the pandemic and to the setting up of a HR specific helpline to deal with Covid related queries from staff and managers alike. In addition much of our Occupational Health and Wellbeing resources has been focussed on providing specific support to our staff affected by the Covid pandemic, including • Supporting the Covid-19 staff vaccination plan and ensuring via the Staff Vaccine Coordinator that sufficient staff peer vaccinators have been trained. •Development of a Post-Covid Staff Wellbeing Strategy that includes a review of the evidence base, consultation with a wide range of stakeholders. •Development of Occupational Health and Staff Wellbeing Service Improvement Plans. •'Winter Wellbeing/Resilience' presentation developed, introduced by Mark Hackett, to communicate support for staff during continued Covid pandemic. •Developing a staff suicide awareness and prevention campaign. • Supporting Health Board wide virtual Wellbeing/resilience days with Senior Nursing colleagues • Conversion of Mindful & Meaningful Living course (a mindfulness & ACT based resilience based course for staff) to remote delivery, enabling increased capacity and conversion of Managing Your Wellbeing self-management course to remote delivery • Promotion of & support in the delivery of Taking Care Giving Care Mini-rounds across the Health Board (as developed by mental health colleagues) •Continuing to develop the network of 400+ Wellbeing Champions, supported by a regular programme of workshops. •Developing workshops regarding Moral Injury, to be delivered remotely. •Implementation of Taking Care Giving Care (TCGC) Mini Rounds •Delivery of TriM (Trauma Risk Management)

As the impact of the second wave of Covid 19 subsides, we have commenced a review of previous and current plans and will adapt these to ensure that our focus continues to be in the correct areas. Initial actions include:

•A focus on the reduction of LTS and STS with an expectation that sickness reduces below 6% •All service groups sickness absence performance to be monitored via grip and control meetings •All service groups to have a rolling 5 hot spot area with targeted approach to improvement •Corporate group high levels of stress related sickness to be further explored ready for next WOD committee •A full action plan to be drafted for Estates & Facilities where sickness absence remains higher than other groups.


This however remains a fluid situation and should we face a further surge of Covid cases affecting our hospitals we may once again need to re assign some of our resources to support the response to best utilise resources in the situation.

What are the main areas of risk?

The effect of the Covid19 pandemic on the health and wellbeing of our workforce particularly leading to increases in mental health and stress related sickness Failure to maintain continued focus on sickness absence performance may lead to levels increasing.


Singular focus on sickness management without measured attention on supporting staff attendance through health and wellbeing interventions congruent with our organisational values. Direct effect on costs in terms of bank, agency and overtime. Increasing levels of sick absence increases pressure on those staff who remain at work. Any increased levels of service change likely to affect health and wellbeing with most likely impact on mental health and stress related sickness. How do we compare with our peers?

In September 20 (the latest month's data available), the in month differential between SBU and the all-Wales performance was 1%.



2.2 HARM FROM REDUCTION IN NON-COVID ACTIVITY

Measure 1: % of children regularly accessing NHS primary dental care within 24 months Measure 2: % of adult dental patients in health board population re-attending NHS primary dental care between 6 and 9 months How are we doing? Dental Services remains in the Amber phase of the Covid-19 recovery. All dental practices are open and are able to perform all elements of dental treatments including aerosol generating procedures (AGPs). Practices can now start to recall routine patients for appointments. Over half of SBU dental practices have installed mechanical ventilation systems to reduce the required fallow times following AGPs which has led to an increase in the number of patients able to be seen Demand on urgent dental care services has increased two fold during the pandemic. Calls to the HB Referral Management Centre (RMC) from patients with urgent dental problems but without a regular dentist are consistently 250 patients per week and there is also provision for 40 Out of Hours appointments each weekend. The Dental Contract Reform programme is currently suspended. All GDS practices are following new WG guidance for Q1 and Q2 of 21/22 with the focus on access for new patients and the application of fluoride varnish. The expectation is that Contract Reform will recommence in Q3 but with a newly designed programme and that it will be an opt-out programme rather than opt-in. What actions are we taking? The WG guidelines for GDS in Q1 and Q2 of 21/22 provide all GDS contracts a target for New Patients – adults not seen at the practice in 24 months and children not seen at the practice in 12 months - these targets will ensure that patient access is increased across the whole of Swansea Bay to help tackle the current access problem and long waiting lists for routine dental care All specialist dental pathways have been reactivated and the HB will be conducting reviews of each service during 21/22 to ensure all services are working to maximum efficiency pre-Covid as waiting list times have increased in all areas. A new intermediate oral surgery clinic is being piloted at the Dental Teaching Unit to help reduce the OS waiting list • The dental service provision at HMP Swansea has been reviewed and refreshed and a tender exercise will commence in May 2021. What are the main areas of risk? Provision of Paediatrics GA within the community outside of national guidance which is considered medical safety risk. Continued cancellations and workforce challenges with reactivation of the special care dentistry list (POWH site) • Continued rise in the demand for urgent access. How do we compare with our peers? Total patients seen in 20/21 compared to 19/20: Child Total Adult Urgent Patients Patients Patients Patients SBU HB 28% 30% 22% 103% 24% Wales 29% 31% 100%



Measure 1: % patients starting first definitive cancer treatment within 62 days from point of suspicion

How are we doing?

- The root cause of delays is capacity issues across tumour site pathways, with both a reduction in theatre and OPD capacity due to Covid restrictions that are in
 place. Diagnostics is also challenged with similar concerns, although we have seen some improvements in Radiological investigations and Endoscopy in recent
 weeks.
- There has been an increase in GP referrals and incidental findings, which could be indicative of the re-introduction of some services within the Health Board.
- Incidental findings via diagnostic imaging increased by 103% in February compared to January.

What actions are we taking?


- More focus is being placed on outpatient capacity, reviewing the allocation of capacity as per the theatre prioritisation process.
- Focused weekly meetings particularly on backlog, endoscopy and capacity.
- Cancer Performance Recovery Plan in development; detailed improvement plans centred on Urology, Gynaecological, Upper & Lower GI.
- Re-zoning of theatre areas under consideration.
- Reconfiguration of the utilisation of theatre capacity on all sites.
- Five additional cancer trackers to commence in post in April 2021
- The additional Endoscopy capacity introduced to reduce backlog has resulted in improved performance for both Upper and Lower Gastrointestinal pathways. Additional capacity agreed to at least end of April 2021, with ongoing discussion as to how we can continue this additional capacity. Locum Consultant commenced in post 21st February.
- STT protocols agreed with primary care clusters on the 11th February.
- GA hysteroscopies are challenging due to the requirement for an inpatient bed and theatre capacity. Which is impacting on Gynae pathways, solutions to address this are being worked through.
- From 25th February, theatre capacity was made available at Neath Port Talbot for Lower Gastrointestinal patients, this has resulted in additional Upper Gastrointestinal theatre capacity (1 list) being made available at Morriston.
- Additional theatre capacity for Urology under review.
- RALP (Robotic Assisted Laparoscopic Prostatectomy) lists reinstated at University Hospital of Wales.

What are the main areas of risk?

• Urology; Gynaecology; Upper & Lower GI pathways have been identified in particular as pathways with high volumes in terms of throughput, backlog and breaches. Actions above have been identified as a minimum, with further detailed review of these pathways in relation to the National Optimal Pathways is underway.

How do we compare with our peers?

- All Wales performance was 60% for February 2021. The performance for SBUHB was 56%.
- BCU HB 67%; HDda UHB 66%; AB UHB 57%; C&V UHB 54%; CTM UHB 52%.



| 1 - | % of radiotherapy | v waiting times | Scheduled (21 | Dav Target / | 28 Day Target) |
|-----|-------------------|-----------------|---------------|--------------|----------------|
| | | | | | |

- 2 % of radiotherapy waiting times Urgent SC (7 Day Target / 14 Day Target)
- 3 % of radiotherapy waiting times Emergency (Within 1 Day / 2 Days)

4 -% of radiotherapy waiting times Elective Delay (21 Day Target / 28 Day Target)

How are we doing?

- 1. The number of patients who started treatment in March was 209. This is the highest number we have seen since January 2018. Urgent SC patients we had 4 patients that breached 14 days, 3 due to planning issues
- 2. For Emergency patients we continue to deliver 100% with all patients being treated in 1 day
- 3. Elective delay patients remain a challenge, we had 42 patients categorised as elective delay, with 3 patients not treated within the maximum target time of 28 days.

What actions are we taking?

- Monthly stakeholder meetings, which include the major staff groups involved in radiotherapy have been implemented to review the data on breach reasons to enable learning to inform changes to processes if necessary.
- We have undertaken hypo fractionation of breast radiotherapy (RT) and have just submitted business case as part of annual plan to offer hypo fractionation for Prostate RT.
- We will start commencing outsourcing of 70 prostate RT cases within the next 4-6weks at Rutherford to continue to support, improving our performance.

What are the main areas of risk?

- Age and capability of our Linac machines we currently have 3 new Machines and 1 old machine. This will give us 1 old machine, which is out of support from the supplier due to age and breakdown risks exist. This case for replacement for Lin C is in with Welsh Government and we hope to be operational by March 2021. New CT replacement scanner is due to go operational at end of May 21.
- Capacity on machines remains main concern. Currently losing treatment capacity monthly due to breakdown of Lin C.


How do we compare with our peers?

Comparison to high-income countries around the world, Linac's per million population. Demark has 3.37, Japan 6.75, Canada 7.5. UK wide – 5.2. In Wales Cancer centres compare as table below

| | LINACS | EXPANSION PLANS | POP'N (MILLION) | LINACS/MILLION POPN |
|-------|--------|-----------------|-----------------|---------------------|
| VCC | 8- | 10 | 1.5 | 5.1/6.6 |
| NWCTC | 3.5 | 4 | 0.9 | 5.0/5.5 |
| SWWCC | 4- | 5 | 0.7 | 4.4/5.5 |


Data Source- IAEA DIRAC

We currently re-reviewing our work on workforce comparison across centres. Performance of these new targets across 3 centres in Wales is challenging and as we understand it all 3 centres are struggling to deliver.



| Measure 1: Number of patients waiting more than 8 weeks for specific diagnostics (excluding Endoscopy) | | | |
|--|--|--|--|
| Measure 2: % patients waiting less than 8 weeks for specific diagnostics (excluding Endoscopy) | | | |
| How are we doing? | | | |
| There were 4,554 patients waiting over 8 weeks for reportable diagnostics as at the end of March 2021. | | | |
| The breakdown for December 2019 is as follows: | | | |
| Cardiac | | | |
| Echo Cardiogram = 630 | | | |
| Cardiac Magnetic Resonance Imaging (Cardiac MRI)= 177 | | | |
| Cardiac Computed Tomography (Cardiac CT)= 294 | | | |
| 24 Hour Tape / Holter = 158 | | | |
| 24 Hour Blood Pressure Monitoring = 1 | | | |
| Diagnostic Angiography = 2 | | | |
| Doppler Stress Echocardiogram = 8 | | | |
| Sleep Studies = 33 | | | |
| Myocardial Perfusion Scan = 25 | | | |
| Trans Oesophageal Echocardiogram (TOE)= 14 | | | |
| • Cystoscopy = 32, Vascular Tech = 17, Fluoroscopy = 25, Electromyography = 708, NCS = 177, Non-Cardiac MRI = 121, Non Obs Ultrasound = 89, Nuclear | | | |
| Medicine = 18, Endoscopies = 2,037 | | | |
| What actions are we taking?, | | | |
| <u>ECG</u> – additional weekend work and additional activity provided by Swansea (including potential pilot scheme with primary care) | | | |
| Endoscopy • ID Medical Insourcing 40 sessions per month from NPTH agreed Q1/Q2 2021/22. • WLI sessions agreed funding for 40 sessions per month | | | |
| agreed Q1/Q2 2021/22. • Endoscopy capacity and Demand plan completed and awaiting approval | | | |
| • <u>Radiology</u> • At risk recruitment for MR has commenced. No applications from experienced candidates received. Review of MRI recruitment advert being | | | |
| undertaken currently with a view to updating and going out to advert again by end of w/c 10 th May 2021. • Scoping meeting with HR w/c 3 rd May to map out | | | |
| OCP timeline for extended working days in MRI/CT. • MRI extended day shift pattern trial commenced. 2 nd week 10 th May 2021. • Work progressing to | | | |
| develop the Radiology Cancer dashboard to support performance management and pathway improvement for cancer and RTT. • Meeting with IT held 6th | | | |
| May 2021 to map out steps for securing Health Board solution for home workstations for 5 consultants – capital requirements circa £50k. • Service | | | |
| develop weekly monitoring report for inpatient diagnostic access times. • Workforce resource requirements for extended working days 7 days a week across | | | |
| all Health Board scanners completed. • Other option for possible cost-effective staffed MRI scanner capacity currently being explored. • Radiology Plan | | | |
| being finalised by 14 th May 2021. | | | |
| What are the main areas of risk? | | | |
| Approval of an investment plan for all diagnostic specialties | | | |
| Endoscopy Nursing workforce capacity limitations due to vacancy, shielding and sickness. Ability to recruit and retain sufficient workforce to meet service | | | |
| demand is the most significant risk to service sustainability. Work force constraints have resulted in the service becoming reliant in recent years on | | | |
| outsourcing / insourcing services • Capacity for new referrals being met at the expense of patients requiring surveillance or 'recall' procedures. • Extra time | | | |
| and space for procedures, because of increased infection control and cleaning procedures | | | |
| Radiology • Ability to recruit qualified staff to update MRI/CT/ and NOUS • Timely access to reporting for some inpatient and cancer patients for sub | | | |
| specialty areas •Sub specialty capacity issues in NOUS (Paediatrics/Head and Neck) due to hard to recruit to areas) | | | |
| How do we compare with our peers? | | | |
| - Best in Wales in the number of >8 week breaches (excluding Endoscony) | | | |

• Best in Wales in the number of >8 week breaches (excluding Endoscopy)



Measure 1: Number of patients waiting more than 8 weeks for Endoscopy Measure 2: % patients waiting less than 8 weeks for Endoscopy Measure 2: % patients waiting less than 8 weeks for Endoscopy

How are we doing?

- The Health Board had achieved and maintained a zero position for patients waiting over 8 weeks for endoscopy up to the end of March 2020. Due to the COVID pandemic overnight the scheduling of all routine and urgent Endoscopy procedures ceased with a focus on Inpatient emergency activity and Urgent suspected cancer cases. The number of patients waiting over 8-weeks has increased significantly month on month due to the restrictions that have impacted upon the ability to schedule and these include AGP policy, social distancing and air exchange turnaround times.
- Endoscopy continues to see a significant increase in urgent suspected cancer referrals. The majority of these continue to be in the area of Lower Gastroenterology referrals internally from surgical specialties. The demand for Inpatient endoscopy has also increased as well as the complexity of the cases due to the late presentation of patients.
- DNA rates continue to remain low at 3%.
- Surveillance waits for upper GI Endoscopy have also increased

What actions are we taking?


- Utilising all available funded capacity as well as short term initiatives such as WLI backfill. Current agreement for funding until the end of August 2021.
- Insourcing 40 sessions a month in NPTH Unit.
- Ongoing additional funding for WLI and Insourcing support confirmed for Q2 2021/22.
- Continued focus on effective triage of referrals with the pending implementation of Straight to Test. The optimum Lower GI pathway has been agreed with Primary Care. The planned live date for full implementation of STT is the 01/06/2021.
- An Endoscopy Capacity and Demand Plan has been submitted for 2021/2022 for Swansea Bay University Health Board (SBUHB) and provides a plan to
 address current capacity issues and provides detailed plans in order for SBU Health Board to deliver a maximum waiting time for Endoscopy of 8 weeks.
 The plan is a combination of a more sustainable approach to achievement of the waiting time targets as well as a continued but decreased short- term
 capacity solution. The plan combines efficiency gains, increased productivity with increasing workforce to allow the service to move towards a closure of the
 known gap in capacity and also supports the move towards management of demand in a more robust and effective way. A national focus on developing an
 agreed all Wales capacity and demand tool is underway and SBUHB are active members of the National Endoscopy Demand and Capacity sub-group.
- The HB team are active participants of the National Workforce Subgroup and have attended all scheduled meetings. A workforce survey has been undertaken recently upon the request of the National Endoscopy Programme Lead.
- Surveillance Endoscopic waits in the HB are a risk and immediate action planned and implemented to review how high risk patients are managed. This includes a clinical review of the longest waiting surveillance patients by the three clinical leads. Risk stratification process being adopted.

What are the main areas of risk?

- Urgent activity being displaced by cancer and inpatient patients with significant pressures in Gastroenterology.
- Ability to maintain the number of additional sessions undertaken with a very small group of Endoscopists.
- Workforce constraints
- Covid restrictions with reduced capacity due to air exchange, social distancing and infection control procedures.

How do we compare with our peers?

• SBUHB compare well to peers in Wales in relation to waiting times performance.



Measure 1: Number of patients waiting more than 14 weeks for a specified Therapy

How are we doing?

Three areas are currently breaching (Speech & Language, Audiology and Nutrition & Dietetics) with Podiatry showing a recovered position from February 2021. Below are the main identified risks for a breaching position for each service:

Audiology •Current performance is a reflection of the backlog generated during four months of cessation of the service and eight months of staff redeployment in 2020. Steady gains have been made in the numbers of people waiting over 14 weeks since the New Year. •Capacity continues to be around 75% of normal capacity due to social distancing and infection control requirements and so a significant increase in referrals to normal levels will mean that progress against the target will slow. •Remote elements for patients who are digitally enabled (approximately 1/3) continues to provide some mitigation to this reduction in efficiency **Nutrition & Dietetics** •COVID 19 – non essential services stopped •Discontinuation of face to face group education programmes •Reduced capacity within initial virtual education sessions •Paediatric Staffing Capacity – vacancies during period •Referral levels returning to pre COVID levels •Majority of patient waiting >14 weeks are in adult weight management service

Speech and Language Therapy •Breaches within the paediatric services only - and can be accounted for by the following factors; 1. Ongoing Covid-19 Restrictions - This is largely due to restrictions in schools/nursery settings, access to, and maintenance of, clinical clean spaces, & staff sickness/self-isolation. 2. Demand on our services has increased with highly complex and time consuming patients. 3. 25% of SALT clinical time is allocated to managing the 14 week wait. 4. High vacancy factor.

What actions are we taking?

As part of internal monitoring and scrutiny of underperforming areas, each service has developed an action plan:

Audiology • Action plan in place to recover against target by end of June 2021 • Reset of face to face appointments •Staff continue to ensure that longest waiters are targeted. • Trial on the benefits of remotely programmable hearing aids continues in order to assess whether these can provide a benefit in reduction of F2F appointments required for follow-up and review.

Nutrition & Dietetics • Action plan in place to recover against target by end of July 2021 • Adult weight management service Virtual Weight Management Group education programmes re-established February 2021 • Increased capacity within core group sessions from April 2021. Capacity 50 patient per 6 weeks. Groups to be fully utilised to reflect drop off and DNA rates • Additional Foodwise sessions offered with delivery from March, temporary increase in capacity within service utilised. • Development of alternative resources for people unable to access virtual education offer • Rolling programme of evening education programmes has been re-established from end April 2021.

Speech and Language Therapy •Action plan in place to recover against target by end of **December 2021** •Each therapist has been allocated a specific number of patients which must be seen in the next 10 weeks. They are accountable to this through regular planning meetings. •Review of patients on the initial referral waiting list to ensure they continue to require assessment. •Additional sessions are being made available to manage this waiting list from other areas of the services. •Where possible, assessments are being carried out on 'Attend Anywhere'. It should be acknowledged that this method of assessment is only suitable for a small percentage of the caseload. •Individual school risk assessments are being reviewed to establish whether schools are able to allow children in different bubbles to be seen on the same day, and whether it is possible to visit more than one school in a day. •There is hope to increase access to clinical spaces within the HB through collaboration with Estates in PCTGs •Recruitment of additional staff through service re-design to support demands on waiting list. The action plan & recovery schedules are being monitored within the PCT Group and reported on a fortnightly basis against their recovery trajectories via Reset & Recovery Silver Operational Group meeting.

What are the main areas of risk?


Audiology - Increased referral rates during recovery programme would impact on timescales.

Nutrition & Dietetics - Recruitment to vacancies particularly in paediatrics

Speech and Language Therapy • Difficulties recruiting into vacancies. • Anticipated increase in referrals as schools return to assessment in the summer term. • Interruptions in access to CYP at school sites due to Covid 19 restrictions. • Reduced capacity due to the demands of ALN upskilling/training events.


How do we compare with our peers?

The Health Board is performing as well as or above our peers




Appendix 1- Integrated Performance Report

| Measure 1: Number of potients weiting more than 26 weeks for referral to treatment (PTT) |
|---|
| Measure 1: Number of patients waiting more than 36 weeks for referral to treatment (RTT) Measure 2: Number of patients waiting more than 26 weeks for first OP appointment |
| Measure 3: % patients waiting less than 26 weeks for referral to treatment (RTT) |
| How are we doing? |
| |
| • 21,750 Stage 1 >26 weeks |
| • 32,411 >36 weeks |
| • 27,226 >52 weeks |
| T&O , ENT, Ophthalmology are the big ticket items in all three performance measures |
| |
| What actions are we taking? |
| A Planned Care Recovery Programme Board has been established to oversee the recovery programme for RTT. The initial plans include |
| A Haimed Care Recovery Programme Board has been established to oversee the recovery programme for RTT. The initial plans include Advice and guidance (via Consultant Connect) to be introduced in the top 10 specialties with highest number of patients waiting by June 2021 and in all specialties by Sept 2021 to assist in managing demand from Primary Care Investment in primary care to reduce demand for secondary care referrals |
| Improved access to diagnostics for primary care |
| Independent sector capacity to be utilised to support the reduction of waiting times in longest waiting specialties including orthopaedics, ophthalmology and ENT |
| o Demand and capacity plans developed for all specialties outlining actions to reduce waiting times including outsourcing and additional internal capacity |
| Plans for additional orthopaedic capacity at NPT Hospital |
| Maximising the surgical activity that can be undertaken in Singleton Hospital |
| |
| |
| |
| |
| |
| |
| What are the main areas of risk? |
| Approval of capital funding to develop orthopaedics solutions |
| Securing independent sector capacity |
| Development of HDU/PACU to support additional surgical activity at Singleton |
| |
| |
| |
| How do we compare with our peers? |
| Better than Wales %age of patients waiting >36 weeks |
| In line with other Health Boards %age Stage 1 patients >26 weeks |
| |




| Measure 1: The number of patients waiting for a follow-up outpatient appointment | | | | |
|--|---|--|--|--|
| M | Measure 2: The number of patients waiting for a follow-up outpatient appointment who are delayed by over 100% | | | |
| How are we doing? | | | | |
| ٠ | The impact of the Covid -19 pandemic has resulted in a decrease in appointments available to patients, even though virtual appointments have been utilised. This | | | |
| | has still lead to delays with patients having appointments which is reflected in the increase in the number of patients waiting over 100%. This has resulted in us not | | | |
| | being able to reach March 2020/21 targets. | | | |
| ٠ | The number of patients on a follow up waiting list (booked & un-booked) with & without a clinical review date has increased from 120,962 (September 2020) to | | | |
| | 121,403 (March 2021) (0.4%). | | | |
| • | Number of patients waiting for a follow up delayed past their target date – over 100%; Has increased from 24,472 (Sept 2020) to 29,316 (March 2021). | | | |
| N | /hat actions are we taking? | | | |
| ٠ | Additional funding has been released by the Health Board to support medium term validation reviews of the Follow up lists – being led by Morriston Delivery Unit. | | | |
| ٠ | New deliverables have been put in place as of March 2021. The outpatient transformation team are implementing consultant connect and Dr Doctor quick question | | | |
| | validation into the top 10 services | | | |
| ٠ | Working with the national Outpatient Modernisation Working Group has been refreshed and this is actively taking forward new measures to address these pressures | | | |
| | which are being seen across Wales. Actions include improved digital access for patients, virtual consultations, consultant connect available for clinicians in key | | | |
| | departments and validation of waiting list over 100% to allow transfer of patients onto the correct pathways SOS/PIFU). | | | |
| • | The Health Board has refreshed the Outpatient Modernisation Group and it has put an advertisement out for a new clinical lead, after Dr Phil Coles departure, to | | | |
| | facilitate clinical engagement and build a bridge between the outpatient transformation teams targets and benefits with clinical targets. | | | |
| • | Monthly Outpatient transformation meetings are being conducted with biweekly outpatient recovery meetings. The membership of these will be reviewed to transform | | | |
| | these groups to a more performance driven group to allow working towards achieving deliverables pretend by the Chief Executive Officer. | | | |
| • | An outpatient dashboard has been created by the digital team to allow for concise and accessible facilities for service user to monitor and propose action on waiting | | | |
| _ | lists. The aim is to push workshops and to allow for smooth running utilisation of this across the Health Board. | | | |
| • | The health board have brought in Productive Partners for a 6 week interval to allow for promotion and communication across the Health Board in Primary and Secondary Care of Consultant Connect. This team will be looking at the communication of this project and dealing with the barriers and concerns the transformation | | | |
| | team are experiencing in regards to the role out and the take up of consultant connect. | | | |
| ١٨ | hat are the main areas of risk? | | | |
| V | The lack of clinical engagement from service managers regarding implanting Dr Doctor Quick question validation and the execution of this within the top 10 services. | | | |
| | Promotion of Consultant connect within Primary and Secondary care to ensure there is awareness of the services and availabilities to ensure paramount | | | |
| • | | | | |
| | engagement with the services. This will ensure that only essential referrals are made and will prevent unnecessary waiting list times. | | | |
| • | The lack of resources available regarding staff and space for validation process. | | | |
| | | | | |
| L | aw da wa compare with our poore? | | | |
| | ow do we compare with our peers? | | | |
| • | SBUHB has had highest impact when implementing Dr Doctor validation process and is predicted to be more advanced with this in comparison to neighbouring | | | |
| | Health Boards. Most Health Boards have experienced a deteriorating position in the number of patients waiting for an outpatient follow up (booked and not booked) who are delayed pagt their target date for planned are specialties and are as in SPLIHP, implementing new plans with traction and page | | | |
| | who are delayed past their target date for planned care specialties and are, as is SBUHB, implementing new plans with traction and pace. | | | |
| 1 | | | | |



| Measure 1 | : Total antibacterial items per 1,000 STAR-PUs (specific therapeutic group age related prescribing unit) |
|-----------------|---|
| | re doing? |
| Swans Decerr | ea Bay University Health Board (SBUHB) has seen the second highest percentage reduction (21.98%) in the last 12 months (December 19 vs ber 20). |
| Long t | erm trend continues to show a decrease but we remain an outlier in terms of volume of antibiotics prescribed in Wales. |
| Vhat action | ons are we taking? |
| | I team of antimicrobial Pharmacists, led by a Consultant Pharmacist, are running stewardship projects across both sectors. |
| | udit for 2021/2022 will focus on management of sore throat, including severity assessment and the decision to treat. |
| Antibio | tic-focused prescribing leads at a cluster level will be held and practices asked to submit action plans based on practice prescribing data |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| What are | he main areas of risk? |
| Not be | ng able to maintain the on-going reductions in total antibacterial usage. |
| | |
| | e compare with our peers? |
| | B is currently the second highest prescribers of antibiotics in Wales. This outlier position correlates with the highest <i>C.difficile</i> rate in Wales and cant proportion of the Health Board <i>C.difficile</i> cases (45%) being identified in the community. |
| | |

| | | PATIE | NT EXPE | RIEN | CE | | | | | | | | | | | |
|-----------------------|----------------------|------------------------------------|---------------|--------|---|----------|---------------|--------|--------|--------|--------|--------|-----------------------------|---------|--------|------------------------|
| Quadrant of Harm: | Harm from reduc | | xecut ead: | ive | Pam Wenger, Director of Corporate Governance | | | | | | | | | | | |
| Quadruple Aim: | Quadruple Aim 3 | | | | | | | F | Period | I: Mar | rch 20 | 21 | | | | |
| | motivated and su | ustainable. | | | | | Loca Targe | - | WG | Targ | | S | urrent tatus hst targ | | (12 | ement month end) |
| Measure 1: Number of | f friends and family | surveys completed | | | | | Increa | se | | N/A | | | \checkmark | Ì | 1 | |
| Measure 2: % of who | would recommend | and highly recommend | | | | | 90% |) | | N/A | | | X | | Ļ | |
| Measure 3: % of all-W | ales surveys scorir | ng 9 or 10 on overall satisfaction | | | | | 90% |) | | N/A | | | \checkmark | | Ļ | |
| (1) Number | of friends and far | nily survey s completed | | | (2) % | ℅of w | ho wo | uld re | ecomn | nend | and hi | ighly | recom | menc | ł | |
| 3,000 | | | | Mar-20 | Apr-20 | May-20 | lun-20 | lul-20 | Aug-20 | Sen-20 | Oct-20 | Nov-20 | Dec-20 | lan-21 | Feb-21 | Mar-21 |
| 2,500 | | | | | 747.20 | 11127 20 | 5411 20 | 201 20 | 100 20 | 50p 20 | 000 20 | | 000 20 | 2011 22 | 100 21 | |
| 2,000 | | | MH&LD | 44% | 36% | 57% | 57% | 33% | 41% | 39% | 19% | 41% | 21% | 36% | 88% | 73% |
| 1,500 | | _ | Morriston | 96% | 98% | 94% | 94% | 94% | 83% | 91% | 82% | 86% | 70% | 76% | 82% | 86% |



| _ | Morriston | 96% | 98% | 94% | 94% | 94% | 83% | 91% | 82% | 86% | 70% | 76% | 82% | 86% |
|----------|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | NPT | 97% | 60% | 67% | 47% | 68% | 92% | 94% | 90% | 75% | 67% | 58% | 32% | 75% |
| _ | PCCS | 88% | 84% | 77% | 88% | 91% | 79% | 74% | 65% | 80% | 62% | 76% | 77% | 90% |
| Mar-z | Singleton | 95% | 93% | 96% | 83% | 92% | 87% | 96% | 88% | 87% | 85% | 85% | 92% | 87% |
| Σ | HB Total | 95% | 90% | 92% | 87% | 91% | 83% | 93% | 82% | 84% | 77% | 79% | 85% | 87% |
| | | | | | | | | | | | | | | |

(3) % of all-Wales surveys scoring 9 or 10 on overall satisfaction

| | Mar-20 | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-2 |
|-----------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|
| MH&LD | - | - | - | - | 0% | 100% | 100% | 100% | - | - | - | - | 50% |
| Morriston | 100% | 100% | 100% | 67% | 90% | 80% | 79% | 58% | 100% | 33% | 80% | 71% | 90% |
| NPT | 67% | - | - | - | 100% | 100% | 90% | 100% | - | 67% | 67% | 100% | 1009 |
| PCCS | 100% | - | 100% | 100% | 94% | 83% | 100% | 100% | 80% | 67% | 90% | 100% | 1009 |
| Singleton | 90% | 95% | 100% | 67% | 90% | 82% | 79% | 90% | 86% | 80% | 77% | 95% | 92% |
| HB Total | 90% | 95% | 100% | 79% | 91% | 83% | 84% | 79% | 85% | 65% | 81% | 94% | 93% |

Source : NHS Wales Delivery Framework, all-Wales performance summary (April 2021)

Measure 1: Number of friends and family surveys completed

Measure 2: % of who would recommend and highly recommend

Measure 3: % of all-Wales surveys scoring 9 or 10 on overall satisfaction

How are we doing?

Health Board Friends & Family patient satisfaction level in March 2021 was 87% and 1,050 surveys were completed:

- Neath Port Talbot Hospital (NPTH) completed 16 surveys for March, with a recommended score of 75%.
- Singleton Hospital completed 453 surveys for March, with a recommended score of 87%.
- Morriston Hospital completed 326 surveys for March, with a recommended score of 86%.
- Mental Health & Learning Disabilities completed 11 surveys for March, with a recommended score of 73%.
- Primary & Community Care completed 255 surveys for March, with a recommended score of 90%.

What actions are we taking?

Friends and Family Survey. Due to the current pandemic we have stopped collecting paper feedback and it is only available online, this explains why figures are so low at this current time. With cases dropping we are in talks of collecting paper feedback again from all of the hospitals.

March data: Due to the close of the SNAP system there were 162 cases from the Mass Vaccination Centre (MVC) that were unable to link to the month end data for March. This was discussed with the MVC managers and all agreed to populate the new Civica system with the missing 162 cases for April's data. This has been actioned.

New patient feedback system - Civica. Civica is built and live enabling us to capture feedback. All surveys are now up and running online, including the All Wales surveys and the online link for Friends and Family has been pushed out to over 2,000 iPads across the Health Board.

Bay Blood Testing Service/Mass Vaccination Centres. The Anti Body Testing Service has been set up on Friends and Family and for the month of March they received a 96% satisfaction score. The 3 MVC's have also been set up on the new system to capture Friends and Family data, they will be doing paper and online.

What are the main areas of risk?

• The Main risk is not having the system set up and collecting feedback.

How do we compare with our peers?

• Monthly/bi monthly data not available on an all Wales basis to compare.

| | | | | | | COMPL | AINTS | | | | | | | | |
|---|--|---|----------------------------------|---|---------------------------------|--|---|--|---|--|--------------------------|---------------------------------------|--|---------------------------------|---------------------------------|
| Quadrant of Harm: | Harm from reduc | ion in r | non-Co | vid activ | ity. | | | | Ex Lea | ecutive ad: | Pamela Govern | • | er, Direct | tor of Co | rporate |
| Quadruple Aim: | Quadruple Aim 3 | | | nd socia | l care w | orkforce | in Wale | es is | | | | | Per | iod: Ma | rch 2021 |
| | motivated and su | stainab | le. | | | | | | | Local Target | WG Ta | - | Curre Statu (against t | us | Movement (12 month trend) |
| Measure 1: Number o | f new formal complai | nts rec | eived | | | | | | 12 | Month ↓ | N/A | | X | | 1 |
| Measure 2: % of respo | onses sent within 30 | working | g days | | | | | | | 80% | 75% | ó | \checkmark | | 1 |
| Measure 3: % of ackn | owledgements sent w | vithin 2 | workin | g days | | | | | | 100% | N/A | ۱ | \checkmark | | → <u> </u> |
| | 60 40 20 0 Sep- MH & LD | | | ston Hosp | | NPT | Dec-20 Hospital | Jan- | PCCS | Feb-21 | Ma gleton Hos | r-21 spital | | | |
| | | Lob 20 | Mar-20 | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | | Oct-20 | Nov-20 | Dec-20 | Inc. 24 | | |
| | | | 1101-20 | - Apr 20 | 11107-20 | | | | 1 JCP-20 | 000-20 | 1000-20 | | | Feb-21 | |
| MH & LD | | 67% | 67% | 100% | 78% | 63% | 69% | 50% | 80% | 70% | 92% | 75% | Jan-21 73% | Feb-21 64% | |
| MH & LD Morriston | Hospital | | 67% 40% | | 78% 94% | | | | 80% 90% | 70% 86% | 92% 89% | | | | |
| Morriston NPT Hospit | <u> </u> | 67% | | 100% | | 63% | 69% | 50% | | | | 75% | 73% 81% 57% | 64% | |
| Morriston NPT Hospit P&C | tal | 67% 75% 88% 64% | 40% 100% 29% | 100% 88% 75% 83% | 94% 80% 73% | 63% 89% 71% 50% | 69% 88% 100% 80% | 50% 84% 50% 60% | 90% 100% 92% | 86% 67% 67% | 89% 86% 76% | 75% 91% 0% 77% | 73% 81% 57% 63% | 64% 95% 67% 67% | |
| Morriston NPT Hospit P&C Singleton H | tal Hospital | 67% 75% 88% 64% 80% | 40% 100% 29% 58% | 100% 88% 75% 83% 75% | 94% 80% 73% 75% | 63% 89% 71% 50% 83% | 69% 88% 100% 80% 50% | 50% 84% 50% 60% 65% | 90% 100% 92% 63% | 86% 67% 67% 64% | 89% 86% 76% 70% | 75% 91% 0% 77% 70% | 73% 81% 57% 63% 57% | 64% 95% 67% 67% 68% | |
| Morriston NPT Hospit P&C | tal Hospital | 67% 75% 88% 64% | 40% 100% 29% | 100% 88% 75% 83% | 94% 80% 73% | 63% 89% 71% 50% | 69% 88% 100% 80% | 50% 84% 50% 60% | 90% 100% 92% | 86% 67% 67% | 89% 86% 76% | 75% 91% 0% 77% | 73% 81% 57% 63% | 64% 95% 67% 67% | , |
| Morriston NPT Hospit P&C Singleton H | tal Hospital | 67% 75% 88% 64% 80% 76% | 40% 100% 29% 58% 48% | 100% 88% 75% 83% 75% 81% | 94% 80% 73% 75% 81% | 63% 89% 71% 50% 83% 75% | 69% 88% 100% 80% 50% 79% | 50% 84% 50% 60% 65% | 90% 100% 92% 63% 82% | 86% 67% 67% 64% 75% | 89% 86% 76% 70% | 75% 91% 0% 77% 70% | 73% 81% 57% 63% 57% | 64% 95% 67% 67% 68% | |
| Morriston NPT Hospit P&C Singleton H | tal Hospital | 67% 75% 88% 64% 80% 76% | 40% 100% 29% 58% 48% | 100% 88% 75% 83% 75% 81% | 94% 80% 73% 75% 81% | 63% 89% 71% 50% 83% 75% | 69% 88% 100% 80% 50% 79% ent with | 50% 84% 50% 60% 65% 72% in 2 wor | 90% 100% 92% 63% 82% | 86% 67% 67% 64% 75% | 89% 86% 76% 70% | 75% 91% 0% 77% 70% | 73% 81% 57% 63% 57% 71% | 64% 95% 67% 67% 68% | 1 |
| Morriston NPT Hospit P&C Singleton I Health Boa | tal Hospital | 67% 75% 88% 64% 80% 76% (3) | 40% 100% 29% 58% 48% | 100% 88% 75% 83% 75% 81% | 94% 80% 73% 75% 81% | 63% 89% 71% 50% 83% 75% | 69% 88% 100% 80% 50% 79% ent with 2020 | 50% 84% 50% 60% 65% 72% in 2 wor | 90% 100% 92% 63% 82% king da | 86% 67% 67% 64% 75% Ays | 89% 86% 76% 70% | 75% 91% 0% 77% 70% 80% | 73% 81% 57% 63% 57% | 64% 95% 67% 67% 68% |] |

| | easure 3: % of acknowledgements sent within 2 working days ow are we doing? |
|---|---|
| • | The Health Board received 118 formal complaints in March 2021 compared with 87 for March 2020. |
| • | The overall Health Board response rate for responding to concerns within 30 working days was 80% for February 2021, which is above the Welsh Government target of 75%. |
| • | The Health Board continues to consistently maintain the 2 day acknowledgement target at 100%. |
| | |
| w | hat actions are we taking? |
| • | Performance of the 30 day response target is addressed consistently at all Service Delivery Unit (SDU) performance reviews. February's performance for the Health Board was 80%. |
| • | Currently there are 30 open Ombudsman investigation cases; Morriston 11, Singleton 7, Mental Health & Learning Disabilities 5, NPT 3 and ; Primary Care and Community Service 4. |
| • | On a monthly basis, the Health Board conducts a Concerns Redress Assurance Group (CRAG) where the Corporate Complaints Team review recently closed complaints. A 'deep dive' review is undertaken on each Service Delivery Unit in turn, as well as the review of a selection of closed complaints from the other Service Delivery Units. During this review, any agreed actions by the Service Delivery Units are monitored by the Corporate Complaints Team to confirm actions are completed to ensure compliance. CRAG is continually developing and evolving to ensure that the best possible learning and assurance is attained by the Health Board. The Health Board has also introduced CRAG workshops where learning is shared with senior members of the Service Delivery Units. |
| W | hat are the main areas of risk? |
| • | Improve Quality of Complaint responses while achieving the 30 day response rate target, and decrease the number of complaints referred to and upheld by the Public Service Ombudsman. |
| | |
| Ц | bw do we compare with our peers? |

| | | | | | | RESEA | RCH | | | | | | |
|-----------------------|---------------|--------------------|--------------|--------------------|--------|--------------------------------------|-------------|------------------------|-------------|-------------------------|-----------|----------------------------|---------------------------------|
| Quadrant of H | Harm: | Harm fro | m reductio | on in non-C | Covid | activity. | | Executive Lead: | Richard | Evans, Ex | ecutive I | Medical E | Director |
| Quadruple Ai | m: | Quadrup | le aim 4: V | Vales has a | a higł | ner value health and so | cial care | | | | Period | Decemb | per 2020 |
| | | | | | | d improvement and inr on outcomes | novation | Annual Plan Profile | WG T | arget | Sta | rent itus t target): | Movement (12 month trend) |
| (1) Number of studies | patients | recruited in | n Health & | Care Res | earch | Wales clinical researc | h portfolio | 1,651 | 10% Imp | rovement | (againe | (| ↑ ● |
| | patients | recruited in | n Health & | Care Res | earch | Wales commercially s | ponsored | 215 | 5% Impr | ovement | > | K | ↓ ● |
| (1) Num | nber of p | | | Health & portfolio | | Research Wales es | | ents recruited | | n & Care I onsored s | | n Wales | commerciall |
| 2000 | 1/ | 505 | | | | | 250 | 205 | | | | | |
| 1500 1109 | 14 | 505 | | | | 1328 | 200 | 9 | | | | | |
| 1103 | | | | | | | 150 | | | | | | |
| 1000 | | | | 376 | | | 100 | | | | | 36 | |
| 500 | | | 210 | 570 | | | 50 | | 2 | | 21 | 30 | |
| 0 | | | | | | | 0 | | - | | | | 1 |
| 19 | | 20 | 20 | 20 | | 20 | Dec-19 | Mar-20 | Jun-20 | | Sep-20 | Dec-20 | Mar-21 |
| Dec-1 | | Mar-20 | Jun-20 | Sep-20 | | Dec-20 Mar-21 | Jec Dec | /ar | lun | | , ep | Jec | /ar |
| | | ≥ f patients re | | | lies | Target | Numb | er of patients re | | | | | Target |
| | | | | | | Benchm | arking | | | | | | |
| _ | | N | leasure 1 | | | | | | | easure 2 | | | |
| | | Q2 19/20 | Q2 20/21 | | | | | | Q2 19/20 | Q2 20/21 | 12mth | | |
| ļ | LHB | Q1-Q2 19/20 | Q1-Q2 20/21 | 12mth Trend | Rank | | | LHB | Q1-Q2 19/20 | Q1-Q2 20/21 | Trend | Rank | |
| | Wales | 5,759 | 6,378 | r | - | | | Wales | 312 | 73 | • | - | |
| | AB | 384 | 1,838 | • | 1 | | | AB | 55 35 | 0 | _⊎ | 5 | |
| | BCU | 1,006 | 1,097 | • | 3 | | | BCU C&V | 101 | 30 | | 5 | |
| | C&V | 2,341 715 | 1,596 940 | → | 2 | | | C&V | 4 | 0 | | 1 5 | |
| | CTM | 397 | 940 340 | F 🚽 | 4 | | | HDda | 9 | 1 | | 4 | |
| | HDda Powys | 7 | 1 | • | 9 | | | Powys | 0 | 0 | -> | 5 | |
| | SB | 618 | 376 | | 5 | | | SB | 93 | 21 | • | 2 | |
| ŀ | PHW | 78 | 0 | | 10 | | | PHW | 0 | 0 | Ð | 5 | |
| ŀ | Velindre | 192 | 47 | | 8 | | | Velindre | 15 | 21 | ŵ | 2 | |
| | WAST | 2 | 143 | • | 7 | | | WAST | 0 | 0 | Ð | 5 | |
| | WAST | - | | | | | | | | | | | |

Measure 1: Number of patients recruited in Health and Care Research Wales clinical research portfolio studies. Measure 2: Number of patients recruited in Health and Care Research Wales commercially sponsored studies.

How are we doing?

• For measure 1, up to Q3, we had 46 portfolio studies open recruiting 1328 patients.

• For measure 2, up to Q3, we had 12 commercial studies open recruiting 36 patients.

As evidenced from the graphs, the rapid drop off in research in March 2020 was due to the impact of COVID and the requirement to pause most recruiting studies and re-divert resource to opening Covid -19 Urgent Priority Studies (UPH). Within this context, Swansea Bay University Health Board (SBU) contributed significantly to the COVID research effort. Hosting 16 Covid-19 studies including 3 UPH 1a priority studies, we recruited 185 patients into the Recovery study. SBU was also the highest Welsh recruiting site for:

Pregnancy neonatal outcomes (123 patients)

Clarity, a trial looking at impact and immunity for patients with inflammatory bowel disease (121 patients)

Phospcovid Tier 1 (56 patients), a post-hospitalisation study

We were the only Welsh site participating in Sprinter trial looking at inhaled B interferon and the Covid heart study.

Since summer 2020, we developed and implemented a Re-Start plan in line with national guidance and subsequently have been steadily re-opening studies whilst ensuring the Covid research effort continues. As at April 26th 2021, we have re-started 129 studies across various specialities and study types.

What actions are we taking?

• Engagement in UK group developing plans to recover the clinical research landscape in the UK building on the COVID experience.

• Working with Health and Care Research Wales colleagues to build on Covid experience in implementing a One Wales model to setting up studies at pace.


What are the main areas of risk?

- Impact of UK losing studies in globally competitive environment.
- Slow responses time for clinicians to respond to expressions of interest and feasibility.
- There is a general decline in Research & Development activity, especially commercial, in the UK and this may reflect uncertainties around Brexit. One of the few EU institutions to leave the UK immediately was the Medicines and Healthcare products Regulatory Agency (MHRA) which has moved from London to Amsterdam.

The above risks previously reported remain with the addition of COVID recovery, which has delayed many studies from starting or completing on target.

How do we compare with our peers?

Q2 data only available at present. This shows for commercial activity, we were in line with other Health Boards (HBs) sharing the common experience of having temporarily paused studies due to COVID. Equally, for portfolio studies, those HBs who showed an increase in recruitment were all hosting the first tranche of the Covid vaccine studies being hosted in Wales which had large number of recruits.



2.3 HARM FROM WIDER SOCIETAL ACTIONS/LOCKDOWN

Appendix 1- Integrated Performance Report

Measure 1: % of children who received 3 doses of the '6 in 1' vaccine by age 1 Measure 2: % of children who received 2 doses of the MMR vaccine by age 5

How are we doing?

Measure 1: October – December 2020 96.7% of children in the Swansea Bay catchment area received the 6 in 1 vaccine by age 1 year. This is above the 95% target and above the all-Wales average of 95.2%.

Measure 2: October – December 2020 92% of children received 2 doses of the MMR vaccine by age 5. This was below the 95% target and similar to the all-Wales average of 92.1%.

What actions are we taking?

- Waiting lists and cancelled clinics are monitored closely by the primary care team. There is a robust reporting mechanism that includes plans for follow up clinics if required.
- Health professionals (GP's/HV/SN/PN) are advised to check and promote immunisation status at every contact.
- A pilot is underway in collaboration with Abertawe Medical Group, Health Visiting and the Child Health Department to cleanse data for children aged 0-5th birthday held by all three systems/services. This commences May 21 and will last up to 8 weeks. Purpose of the pilot is to ensure core demographics are correct, ensure immunisation status held by all is correct, check that all three lists of children align and add or remove children as required.

What are the main areas of risk?

- The number of resident children who have received 2 doses of the MMR by 5 years remains below the required 95% for herd immunity and leaves the population vulnerable to an outbreak. Swansea is currently 92%, below the 95% target. Those who have had 2 doses of MMR by age 4 are 88%.
- Resident children up to date for all immunisations by age 4 years for Swansea Bay University Health Board (SBUHB) is 87.2% and lower than the same time last year (87.4%)
- Child Health Information System SBAR remains on the Internal Audit Risk Register as red and as an overdue action to be undertaken. Action to reduce health inequalities in immunisation uptake remains hampered by the Child Health Information System not being able to cleanse data regularly. This risk of children being missed or immunisation further delayed is increased due to potential incorrect demographic information or incomplete immunisation history. This related to the pilot above, further work will be progressed if this pilot is successful, but will have a long timescale to complete with every practice.
- Public Health Wales "Inequalities in uptake of routine child hood immunisations in Wales 2018-19" annual report the gap in up to date immunisations at age 4 years between highest and lowest quintile has increased to 8.6% from 7 % in 2017/18. At age 5 years, the gap has increased by 1% to 4.2% from 3.1% in 17/18. This is the most current report.

How do we compare with our peers?

- Measure 1 SBUHB is ranked 4th in comparison to the other Welsh Health Boards for 6:1 and above the Welsh average of 95.2% during this reporting quarter
- Measure 2 SBUHB is ranked 3rd in comparison to the other Welsh Health Boards for MMR x2 slightly above the Welsh average of 92.1% during this reporting quarter

| Quadrant of Harm: | Harm from wider so | cietal actions/lo | ockdown | | | | Executive Lead: | Keith Reid | l, Director of Public | c Health | |
|---|---|-------------------|-------------------------------|--|---|------------------------------|--------------------|---------------|--|------------------------|------|
| Quadruple Aim: | Quadruple aim 1: Pe better prevention an | | | ved health | and well-be | ing and | Annual | WG | Period: Ma | arch 2021 | |
| % uptake of the Seas | onal Flu Vaccine in the | following group | os: | | | | Plan Profile | Target | Current Status (against profile): | Mover (12 m trei | onth |
| Aleasure 1: 65 years | and older | | | | | | | 75% | \checkmark | 1 | |
| | to 64 years in at risk g | roups | | | | | | 55% | × | 1 | |
| Aeasure 3: Children | | | | | | | | N/A | | 1 | |
| | re workers who have di | rect patient cor | ntact | | | | | 60% | \checkmark | <u>↑</u> | |
| leasure 5: Pregnant | | and older, (2) | | | <u> </u> | | | 75% | • | ↓ ↓ | |
| 80.0 60.0 40.0 | % | × | × | | | × | × | | 5 years and older months to 64 years | s @ Risk | |
| | 9% 9% 9% | 2016/17 | 2017/18 | 2018/19 | | 2019/20 | 2020/21 | -∎-6 2 | • | s @ Risk | |
| 60.0 40.0 20.0 | % % % % % | 2016/17 | •• | Benchm | arking | •• | 2020/21 | -∎-6 2 | 6 months to 64 years 2 & 3 yr olds Healthcare Workers | a @ Risk | |
| 60.0 40.0 20.0 | % % % % % | 2016/17 | % Upta | Benchm Ike of Sease | | ccine | 2020/21 | -∎-6 2 | 6 months to 64 years 2 & 3 yr olds Healthcare Workers | a @ Risk | |
| 60.0 40.0 20.0 | % % % % % | 2016/17 SBN | % Upta | Benchm Ike of Sease | arking onal Flu Va | ccine | 2020/21 | -∎-6 2 | 5 months to 64 years 2 & 3 yr olds Healthcare Workers Pregnant Women | 9 @ Risk | |
| 60.0 40.0 20.0 0.0 | % % % % % | | % Upta * Da | Benchm lke of Sease ata up to 23 | arking onal Flu Va rd March 20 | ccine 21 | | | months to 64 years & 3 yr olds Healthcare Workers Pregnant Women | a @ Risk | |
| 60.0 40.0 20.0 0.0 2020/21 (1) 65+ | % % % % % | SBU 75.5% | % Upta * Da | Benchm ke of Sease ata up to 23 BCU | onal Flu Va March 20 C&V | ccine 21 CTaf | HDdA | | s months to 64 years 2 & 3 yr olds Healthcare Workers Pregnant Women | 9 @ Risk | |
| 60.0 40.0 20.0 0.0 2020/21 (1) 65+ (2) 6 mo | 5015/16 % | SBU 75.5% | % Upta * Da AB 78.3% | Benchm ike of Sease ata up to 23 BCU 78.2% | arking onal Flu Va rd March 20 C&V 77.4% | ccine 21 CTaf 75.4% | HDdA 73.6% | | s months to 64 years & 3 yr olds Healthcare Workers Pregnant Women Vys Wales 5% 76.5% 2% 51.0% | a @ Risk | |

Reporting)

Measure 1: 65 years and older

Measure 2: 6 months to 64 years in at risk groups

Measure 3: Children 2 to 3 year olds

Measure 4: Healthcare workers who have direct patient contact

How are we doing?

Measure 1. Uptake is 75.5%, which is above the 75% target and just below the uptake for Wales 76.5%.

Measure 2. Uptake is 49.4%, slightly below the uptake for Wales 51%. Swansea Bay University Health Board (SBUHB) has achieved an improvement in most clinical areas, including the highest uptake patient group of last year: patients with chronic diabetes (61.8%), and respiratory disease patients with Chronic Obstructive Pulmonary Disease (COPD) (63.9%).

Measure 3. Uptake is 53.4%, below the Welsh uptake of 56.3%.

Measure 4. Uptake of staff with direct patient contact is 63.2%, which is an improvement on last year.

What actions are we taking?


All actions in Primary Care Flu Plan overseen by flu and COVID planning group to provide maximum assurance that actions were joined up across vaccination campaigns.

What are the main areas of risk?

Whilst COVID helped to increase public awareness and uptake of the flu vaccine, it also created barriers in individuals' concern about attending healthcare settings and not wanting the flu vaccine close to the timing of the COVID vaccine roll out. Uptake in the 2-3 age group remains a challenge.

How do we compare with our peers?

Compared to other Welsh Health Boards SBU HB is ranked: 4th for patients 65 years and older (5th last year). 4th for patients 6m to 64 years at risk (3rd last year). 5th for children 2 to 3 years (4th last year).



(1) Crisis - % Urgent Assessment within 48 Hours from receipt of referral (2) NDD - % patients receiving a Diagnostic Assessment within 26 weeks (3) P-CAMHS - % Routine Assessment undertaken within 28 days from receipt of referral (4) P-CAMHS - % Therapeutic interventions started within 28 days following assessment (5) S-CAMHS - % ABMU residents that have a valid Care and Treatment Plan (6) S-CAMHS - % Routine Assessment undertaken within 28 days from receipt of referral

How are we doing?

Measure 1: Crisis - Service now operates 7 days a week, and the performance trend shows that compliance against the target is good, and when performance does deteriorate this is down to staff vacancies. Compliance for March is at 100%.

Measure 2: NDD – The referral rate has stabilised at an average of 67 per month over the past 12 months but unsure of the Covid impact of this level so this will be monitored closely now schools have re-opened. Compliance against the target has seen a slight improvement to 30% in March.

Measure 3: P-CAMHS – Compliance against the assessment within 28 days can vary considerably, and the main driver for this is staff vacancies. During the first wave of the pandemic P-CAMHS staff were deployed to other areas of the service to cover staff sickness and this continued until Nov 20. An increase in referrals has been seen with the re-opening of schools, and an increase in demand is expected as a result of the pandemic. Compliance against this target is always challenging and will remain low until all CYP are being seen within 28 days. The service are currently progressing with waiting list initiatives to increase activity. Measure 4: P-CAMHS – Compliance against the 80% target for therapeutic interventions has consistently been achieved during 2020/21. The service prioritises this target since it is seen as a key quality indicator that once young people start their interaction with CAMHS they are seen quickly.

Measure 5: S-CAMHS – Compliance against the Care and Treatment Plan target has also been affected and has seen a slight decline in compliance.

Measure 6: S-CAMHS - Compliance against this target has improved significantly over the last 18 months and the trend has been upwards, however vacancies have contributed to variable levels.

What actions are we taking?

NDD –A paper was presented at the April 2021 Performance and Finance committee. The referral rate has stabilised at an average of 67 per month over the past 12 months but unsure of the Covid impact of this level so this will be monitored closely now schools have re-opened. The paper outlined the long waiting times for initial assessments and also an update on the increased capacity which will be delivered from April 2021 by the appointment of the new staff now in post which will start to reduce the number of patients waiting for an appointment. This also highlighted the remaining demand and capacity gap and backlog of patients who need to be seen to improve performance and reduce waiting times together with further funding required to close this gap. The patient pathway and processes continue to be reviewed by the clinical team. A similar position regarding performance and waiting times is seen across Wales and is being monitored by the NDD clinical team. **CAMHS** – The SCAMHS compliance has deteriorated recently due to vacancies, sickness and internal movement of staff to new posts. The service has also seen an expected increase in demand. The service has maintained a >70% compliance in spite of the increased demand due to COVID 19 until recently. Remedial action is being taken to recover the current position. The PCAMHS position deteriorated due to sickness and redeployment within the team during September to November. The position deteriorated further following the holiday period. However, all staff have since returned and a plan has been put into place to ensure compliance increases. CAMHS have been through a period of significant change over the last year, with the three small CAMHS teams combining to form a single integrated service, which will ultimately see performance and access for young people improve and stabilise. During the pandemic, the service fully implemented a single point of access, and have recruited Emotional Health & Wellbeing officers to provide direct support to schools. The Swansea Serv


Swansea Bay continue to work with CTM, and support them with implementing the agreed multi-agency strategic vision for the Swansea Bay population, including the roll out of a digital platform for online counselling - Kooth which is scheduled to go live at the end of May.

What are the main areas of risk?

The inability to recruit and retain staff is a recurring theme and the relatively small size of the different specialist teams in CAMHS is a concern that SBU is addressing with Cwm Taf via formal commissioning meetings and the introduction of the new service model.

How do we compare with our peers?

There is limited comparative data for CAMHS. An external peer review of the Swansea Bay University Health Board was carried out in February 2021, which found no issues in need of immediate resolution, and the feedback was positive. The report on the outcome of the peer review is expected in May 2021.



| Measure 1: % of assessment by the Local Primary Mental Health Support Service (LPMHSS) undertaken within 28 days from receipt of referral |
|--|
| Measure 2: % of therapeutic interventions started within 28 days following assessment by LPMHSS |
| Measure 3: % of Health Board residents in receipt of secondary Mental Health services (all ages) to have a valid Care and Treatment Plan (CTP) |
| Measure 4: % of patients waiting less than 26 weeks to start a psychological therapy in Specialist Adult Mental Health. |
| How are we doing? |
| Measure 1 – Swansea Bay University Health Board (SBUHB) met the target (80%) for the twelve months excluding CAMHS data. Including CAMHS we met the target five of the twelve months. It should be noted that actual waiting time is irrespective of weekends and bank holidays. Measure 2 - SBUHB met the target (80%) for the twelve months including and excluding CAMHS data Meeting the target does not tell you how many people are waiting or the length of longest waits, but we manage and monitor the lists locally. Measure 3 - This data covers Adult, Older People, CAMHS and Learning Disability Services. SBUHB met the target (90%) for eleven of the 12 months, most recent data for February 91% Measure 4 - The % of patients waiting to start a psychological therapy at end of February 2021 was 100%, as defined as high intensity or specialist psychological therapies (as defined in Matrics Cymru). Referrals for low intensity interventions are excluded. |
| |
| What actions are we taking? |
| The Local Primary Mental Health Support Service (LPMHSS) has benefited from recent additional Welsh Government resources to develop teams and this is allowing them to recruit additional assessors and therapists. The LOMUSS is in the presence of developing a further response of group interventions in order to effect the demend for 4.4 therapy. |
| The LPMHSS is in the process of developing a further range of group interventions, in order to offset the demand for 1:1 therapy. The LPMHSS is supporting the GP cluster networks as they seek to develop bespoke mental health interventions. |
| What are the main areas of risk? |
| Part 1 demand remains under scrutiny due to the potential of an increase in relation to the social, economic and psychological impact of the pandemic. Currently, demand is not exceeding pre-Covid levels and the assessment & intervention targets continue to be met. |
| How do we compare with our peers? |
| February 2021 All-Wales MH1 measure ranged from under 18 (11.1% to 97.5%, SBU 97.5%) target 80%, over 18 (11.4% to 99.1%, SBU 97.6%). All-Wales MH2 measure ranged from under 18 (23.3% to 96.9%, SBU 96.9%), over 18 (60.3% to 98.1%, SBU 98.1%). |

- All-Wales MH3 measure ranged from under 18 (54.7% to 100%, SBU 83.5%), over 18 (68.6% to 92.1%, SBU 90.9%)
- All-Wales MH4 measure ranged from 28.2% to 100%, SBU 100%

3. FINANCE UPDATES

This section of the report provides further detail on key workforce measures.

| Description | Current Performance | Trend |
|--|---|--|
| Revenue Financial Position – expenditure incurred against revenue resource limit | The Health Board's annual plan produces a forecast deficit for 2021/22 of £42.077m. This equates to an expected monthly overspend of £3.506m. The Health Board reported an overspend of £3.541m in April 2021, which is £0.035m above planned deficit. Within the financial position the COVID impact is around £7.7m, which has been met be agreed or anticipated funding. | HEALTH BOARD FINANCIAL PERFORMANCE 2021/22 #1 #12 #13 #14 #15 #16 #11 #18 #19 #110 #112 3,500 3,500 3,000 2,500 2,500 3,541 1,500 1,000 0 Operational Position |

| Description | Current Performance | Trend |
|--|--|---|
| Capital Financial Position – expenditure incurred against capital resource limit | The forecast outturn capital position for 2021/22 is an overspend of £1.223m. Allocations are anticipated from WG which will balance this position. The reported forecast outturn position assumes that £0.552m of disposal income will be received | Capital - Cumulative Performance to Plan |
| Workforce Spend – workforce expenditure profile | The pay budgets are overspent by £0.638m in April 2021. This is after funding has been allocated to support additional costs associated with COVID. Whilst variable pay in April is broadly in line with the average for 2020/21, it must be recognised that there were periods of particularly high variable pay during the peak of the pandemic wave in 2020/21. The variable pay costs for April are around £0.9m higher than the same period in 2020/21. | Variable Pay Expenditure This Year and Last Year 8,000,000 7,000,000 6,000,000 4,000,000 1,000,000 0 0 0 0 0 0 0 0 0 0 0 0 |

| Description | Current Performance | Trend |
|---|---|--|
| PSPP – pay 95% of Non-NHS invoices within 30 days of receipt of goods or valid invoice | The Health Board failed to deliver this target in 2020/21, with the target only being met on three of the twelve months. The target has been met in April 2021, with 95.4% of invoices being paid within 30 days. The main reason for the failure to meet this target is delay in the receipting of goods and services, which prevent invoices being processed for payment. | Percentage of non-NHS invoices paid within 30 days of receipt of goods or valid invoioce |

APPENDIX 1: INTEGRATED PERFORMANCE DASHBOARD

| | | | | | | | | Harm from | m Covid itse | elf | | | | | | | | | | | | | |
|------------|--|-----------------------------|------------------|------------------------|--------------------|-------------------------------|-------------------|----------------------------|--------------------------|----------------------|--------|--------|--------|--------|--------|------------------------|--------|--------|---------------------|--------|---------------------|--------------------|--------|
| Sub Domain | Measure | National or Local Target | Report Period | Current Performance | National Target | Annual Plan/ Local Profile | Profile Status | Welsh Average/ Total | SBU's all- Wales rank | Performance Trend | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Apr-21 |
| w | Number of new COVID19 cases | Local | Apr-21 | 406 | | Reduce | | | | | 1,381 | 303 | 57 | 53 | 66 | 787 | 4,664 | 5,525 | 11,976 | 3,759 | 1,208 | 907 | 406 |
| Tre | Number of staff referred for Antigen Testing | Local | Apr-21 | 11,892 | | Reduce | | | | | 2,281 | 2,785 | 3,102 | 3,329 | 3,564 | 4,765 | 6,460 | 8,201 | 10,065 | 10,749 | 11,115 | 11,683 | 11,892 |
| meas | Number of staff awaiting results of COVID19 test | Local | Apr-21 | 0 | | Reduce | | | | \wedge | 0 | 19 | 16 | 1 | 0 | 38 (as at 10/10/20) | | | 99 (as at 05/01/21) | | 69 (as at 06/03/21) | 2 (as at 11/04/21) | |
| g | Number of COVID19 related incidents | Local | Apr-21 | 74 | | Reduce | | | | $\sim \sim$ | 119 | 67 | 40 | 26 | 39 | 30 | 87 | 141 | 127 | 84 | 63 | 53 | 74 |
| <u>at</u> | Number of COVID19 related serious incidents | Local | Apr-21 | 0 | | Reduce | | | | | 1 | 0 | 2 | 0 | 11 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| e | Number of COVID19 related complaints | Local | Apr-21 | 38 | | Reduce | | | | $\sim \sim$ | 77 | 61 | 39 | 58 | 27 | 30 | 37 | 50 | 83 | 106 | 131 | 98 | 38 |
| 13 | Number of COVID19 related risks | Local | Apr-21 | 2 | | Reduce | | | | ~~~~ | 19 | 20 | 19 | 5 | 8 | 2 | 6 | 7 | 10 | 3 | 3 | 3 | 2 |
| | Number of staff self isolated (asymptomatic) | Local | Mar-21 | 145 | | Reduce | | | | $\sim \sim \sim$ | 851 | 516 | 474 | 422 | 420 | 353 | 329 | 291 | 475 | 218 | 160 | 145 | |
| <u>S</u> | Number of staff self isolated (symptomatic) | Local | Mar-21 | 108 | | Reduce | | | | <u>`</u> | 860 | 292 | 141 | 70 | 36 | 72 | 132 | 294 | 394 | 316 | 156 | 108 | |
| | % sickness | Local | Mar-21 | 1.9% | | Reduce | | | | <u>`</u> | 13.2% | 6.0% | 4.5% | 3.6% | 3.5% | 3.2% | 3.5% | 4.4% | 6.5% | 4.0% | 2.4% | 1.9% | |

| | | | | | | Harm | ۱ from ov | /erwhelmed | d NHS and s | ocial care syste | em | | | | | | | | | | | | |
|------------|---|-----------------------------|------------------|------------------------|-------------------------|-------------------------------|-------------------|----------------------------|---|---|------------|-----------|--------|--------|--------|----------------|--------------|--------|--------|--------|------------------|--------|--------|
| Sub Domain | Measure | National or Local Target | Report Period | Current Performance | National Target | Annual Plan/ Local Profile | Profile Status | Welsh Average/ Total | SBU's all- Wales rank | Performance Trend | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Apr-21 |
| | % of emergency responses to red calls arriving within (up to and including) 8 minutes | National | Apr-21 | 72% | 65% | 65% | 4 | 62.5% (Mar-21) | 1st (Mar-21) | $\sim \sim$ | 70% | 75% | 76% | 74% | 72% | 69% | 66% | 67% | 54% | 67% | 70% | 73% | 72% |
| are | Number of ambulance handovers over one hour | National | Apr-21 | 337 | 0 | | | 2,778 (Mar-21) | 3rd (Mar-21) | ~~ | 61 | 20 | 47 | 120 | 163 | 410 | 355 | 500 | 510 | 195 | 219 | 231 | 337 |
| Ö | Handover hours lost over 15 minutes | Local | Apr-21 | 877 | | | | | | ~~ | 209 | 125 | 178 | 315 | 418 | 1,100 | 916 | 1,474 | 1,804 | 455 | <mark>550</mark> | 583 | 877 |
| nschedule | % of patients who spend less than 4 hours in all major and minor emergency care (i.e. A&E) facilities from arrival until admission, transfer or discharge | National | Apr-21 | 75% | 95% | | | 74.2% (Feb-21) | 6th (Feb-21) | \sim | 78.4% | 83.5% | 87.7% | 80.1% | 80.6% | 76.4% | 77.2% | 75.4% | 72.6% | 77% | 71% | 77% | 75% |
| | Number of patients who spend 12 hours or more in all hospital major and minor care facilities from arrival until admission, transfer or discharge | National | Apr-21 | 631 | 0 | | | 4,768 (Feb-21) | 3rd (Feb-21) | \sim | 131 | 97 | 81 | 223 | 286 | 537 | 494 | 626 | 776 | 570 | 534 | 457 | 631 |
| | % of survival within 30 days of emergency admission for a hip fracture | National | Jan-21 | 65.3% | 12 month 🛧 | | | 74.7% (Jan-21) | 4th (Jan-21) | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | 78.9% | 77.1% | 95.5% | 93.5% | 93.9% | 89.4% | 90.0% | 67.9% | 68.0% | 65.3% | | | |
| NOF | % of patients (age 60 years and over) who presented with a hip fracture that received an orthogeriatrician assessment within 72 hours | National | Jan-21 | 87.0% | 12 month ↑ | | | 60% (Jan-21) | 2nd (Jan-21) | | 79.0% | 80.0% | 82.0% | 83.0% | 83.0% | 84.0% | 84.0% | 85.0% | 86.0% | 87.0% | | | |
| | Direct admission to Acute Stroke Unit (<4 hrs) | National | Apr-21 | 20% | 54.0% | | | 21.4% (Feb-21 | 3rd out of 6 organisations (Feb-21) | \sim | | | 52.7% | 57.4% | 51.4% | 50.0% | 29.8% | 23.7% | 7.1% | 6.8% | 18.2% | 20.4% | 20.3% |
| | CT Scan (<1 hrs) (local | Local | Apr-21 | 30% | | | | | | -~~~ | | | 49.1% | 48.2% | 52.8% | 62.5% | 42.1% | 31.7% | 22.7% | 42.2% | 30.6% | 40.8% | 29.7% |
| υ | Assessed by a Stroke Specialist Consultant Physician (< 24 hrs) | National | Apr-21 | 97% | 85.3% | | | 85.4% (Feb-21) | 1st (Feb-21) | \sim | Data not a | available | 100.0% | 94.6% | 97.2% | 97.5% | 98.2% | 96.7% | 95.5% | 95.6% | 97.2% | 100.0% | 96.9% |
| ti K | Thrombolysis door to needle <= 45 mins | Local | Apr-21 | 25% | 12 month ↑ | | | | | ~~~^ | | | 30.0% | 25.0% | 0.0% | 12.5% | 11.1% | 28.6% | 0.0% | 12.5% | 0.0% | 55.6% | 25.0% |
| ω | % compliance against the therapy target of an average of 16.1 minutes if speech and language therapist input per stroke patient | National | Apr-21 | 47% | 12 month ↑ | | | 43.0% (Feb-21) | 1st (Feb-21) | \bigwedge | | | 30.7% | 44.3% | 61.7% | 80.1% | 86.5% | 65.1% | 63.4% | 65.7% | 61.2% | 55.9% | 47.1% |
| | % of stroke patients who receive a 6 month follow-up assessment | National | Q3 19/20 | 49.6% | Qtr on qtr ↑ | | | 62.2% (Q3 19/20) | 5th out of 6 organisations (Q3 19/20) | | | | | | | | | | | | | | |
| | Number of mental health HB DT oCs | National | Mar-20 | 13 | 12 month ↓ | 27 | 1 | | | | | | | | | reporting terr | | | | | | | į |
| DTOCs | Number of non-mental health HBDToCs | National | Mar-20 | 60 | 12 month ↓ | 50 | × | | | | | | - | | DTOC | reporting terr | porarily sus | pended | | | | | |
| | % critical care bed days lost to delayed transfer of care | National | Q1 20/21 | 26.2% | Quarter on quarter ↓ | | | 5.3% (Q1 20/21) | 2nd (Q1 20/21) | · | | | 2.5% | | | | | | | | | | |

| | | | | | | Harm | from ov | verwhelmed | I NHS and s | ocial care syste | m | | | | | | | | | | | | |
|--------------------------------|---|-----------------------------|------------------|------------------------|--------------------|-------------------------------|-------------------|----------------------------|---|---|-----------|-----------|-----------|-----------|-----------|--------------|--------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Sub Domain | Measure | National or Local Target | Report Period | Current Performance | National Target | Annual Plan/ Local Profile | Profile Status | Welsh Average/ Total | SBU's all- Wales rank | Performance Trend | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Apr-21 |
| | Cumulative cases of E.coli bacteraemias per 100k pop | | Apr-21 | 99.8 | <67 | | × | 59.90 (Mar-21) | 3rd (Mar-21) | | 43.8 | 43.0 | 46.4 | 53.8 | 62.5 | 64.0 | 65.7 | 63.8 | 60.7 | 60.0 | 59.8 | 61.9 | 99.8 |
| | Number of E.Coli bacteraemia cases (Hospital) | | | 12 | | | | (10101-21) | (10121) | | 6 | 6 | 3 | 8 | 8 | 7 | 14 | 5 | 5 | 6 | 6 | 9 | 12 |
| | Number of E.Coli bacteraemia cases (Community) | | Apr-21 | 20 | | | | | | | 8 | 8 | 14 | 17 | 24 | 16 | 11 | 11 | 7 | 12 | 11 | 19 | 20 |
| | Total number of E.Coli bacteraemia cases | | | 32 | | | | | | | 14 | 14 | 17 | 25 | 32 | 23 | 25 | 16 | 12 | 18 | 17 | 28 | 32 |
| | Cumulative cases of S.aureus bacteraemias per 100k pop | | Apr-21 | 40.5 | <20 | | × | 24.85 (Mar-21) | 6th (Mar-21) | \/ | 31.5 | 24.7 | 28.8 | 26.1 | 28.2 | 30.7 | 31.5 | 32.7 | 31.7 | 31.6 | 31.4 | 31.6 | 40.5 |
| | Number of S.aureus bacteraemias cases (Hospital) | | | 4 | | | | | | · | 4 | 2 | 4 | 3 | 5 | 7 | 6 | 7 | 6 | 5 | 7 | 4 | 4 |
| | Number of S.aureus bacteraemias cases (Community) | | Apr-21 | 8 | | | | | | $\sim \sim \sim \sim$ | 6 | 4 | 8 | 3 | 7 | 7 | 6 | 6 | 3 | 4 | 2 | 7 | 8 |
| | Total number of S.aureus bacteraemias cases | | | 12 | | | | | | $\checkmark \checkmark \checkmark \checkmark$ | 10 | 6 | 12 | 6 | 12 | 14 | 12 | 13 | 9 | 9 | 9 | 11 | 12 |
| to I | Cumulative cases of C.difficile per 100k pop | | Apr-21 | 62.3 | <26 | | × | 28.04 (Mar-21) | 6th (Mar-21) | / | 34.4 | 42.9 | 49.5 | 45.3 | 50.2 | 51.2 | 50.4 | 48.4 | 45.7 | 42.0 | 41.5 | 41.1 | 62.3 |
| u con | Number of C.difficile cases (Hospital) | National | | 15 | | | | | | | 9 | 6 | 14 | 7 | 9 | 12 | 12 | 8 | 6 | 3 | 9 | 7 | 15 |
| ction | Number of C.difficile cases (Community) | | Apr-21 | 5 | | | | | | | 2 | 10 | 6 | 4 | 14 | 6 | 3 | 2 | 3 | 0 | 2 | 5 | 5 |
| infe | Total number of C.difficile cases | | | 20 | | | | | | | 11 | 16 | 20 | 11 | 23 | 18 | 15 | 10 | 9 | 3 | 11 | 12 | 20 |
| | Cumulative cases of Klebsiella per 100k pop Number of Klebsiella cases (Hospital) | | Apr-21 | 28.1 4 | | | | | | | 18.8 | 18.4 4 | 21.6 4 | 20.0 | 22.1 6 | 21.0 | 21.9 7 | 23.4 7 | 24.9 8 | 26.4 8 | 25.8 4 | 26.2 1 | 28.1 4 |
| | Number of Klebsiella cases (Tospital) | | | 5 | | | | | | | 5 | 2 | 5 | 2 | 4 | 2 | 2 | 4 | 4 | 5 | 2 | 9 | 5 |
| | Total number of Klebsiella cases | | Apr-21 | 9 | | | | 69 | Joint 1st | | 6 | 6 | 9 | 5 | 10 | 5 | 9 | 11 | 12 | 13 | 6 | 10 | 9 |
| | Cumulative cases of Aeruginosa per 100k pop | | Apr-21 | 9.4 | | | | (Mar-21) | (Mar-21) | | 6.3 | 10.7 | 7.2 | 6.2 | 6.7 | 5.6 | 5.7 | 5.8 | 5.5 | 5.2 | 5.1 | 4.9 | 9.4 |
| | Number of Aeruginosa cases (Hospital) | | 7.0.21 | 2 | | | | | | $\Lambda $ | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 2 |
| | Number of Aeruginosa cases (Community) | | Apr-21 | 1 | | | | | | ~~~~ | 0 | 2 | 0 | 1 | 3 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| | Total number of Aeruginosa cases | | | 3 | | | | 7 (Mar-21) | Joint 2nd (Mar-21) | Λ_{Λ} | 2 | 5 | 0 | 1 | 3 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 3 |
| | Hand Hygiene Audits- compliance with WHO 5 moments | Local | Apr-21 | 96% | | 95% | ~ | (Mar 21) | (Mar 21) | ~~~~ | 98% | 99% | 98% | 98% | 94% | 96% | 97% | 97% | 96% | 95% | 93% | 97% | 96% |
| and | Of the serious incidents due for assurance, the % which were | National | Apr-21 | 0% | 90% | 80% | × | | | $\land \land$ | 7% | 29% | 0% | 0% | 50% | 20% | 0% | 0% | 4% | 0% | 10% | 0% | 0% |
| Serious cidents ar risks | assured within the agreed timescales Number of new Never Events | National | Apr-21 | 0 | 0 | 0 | 1 | | | | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Se cide | Number of risks with a score greater than 20 | Local | Apr-21 | 132 | | 12 month ↓ | × | | | | 109 | 101 | 110 | 115 | 121 | 117 | 130 | 138 | 146 | 148 | 140 | 142 | 132 |
| Ē | Number of risks with a score greater than 16 | Local | Apr-21 Mar-21 | 217 36 | | 12 month ↓ 12 month ↓ | X | | | | 202 25 | 193 29 | 204 18 | 204 19 | 210 37 | 206 44 | 224 59 | 224 42 | 238 | 242 51 | 233 48 | 230 36 | 217 |
| cers | Number of pressure ulcers acquired in hospital Number of pressure ulcers developed in the community | | Mar-21 Mar-21 | 26 | | 12 month ↓ | | | | | 25 34 | 33 | 34 | 28 | 25 | 21 | 34 | 42 29 | 26 | 25 | 48 24 | 36 26 | |
| e Ul | Total number of pressure ulcers | Local | Mar-21 | 62 | | 12 month ↓ | × | | | ~~~ | 59 | 62 | 52 | 47 | 62 | 65 | 93 | 71 | 87 | 76 | 72 | 62 | |
| ssur | Number of grade 3+ pressure ulcers acquired in hospital Number of grade 3+ pressure ulcers acquired in community | Loodi | Mar-21 Mar-21 | 1 2 | | 12 month ↓ 12 month ↓ | × | | | | 2 4 | 0 | 1 9 | 0 4 | 4 5 | 0 | 4 | 4 | 3 | 2 | 3 | 1 2 | <u> </u> |
| Pre | Total number of grade 3+ pressure dicers acquired in community | | Mar-21 | 3 | | 12 month ↓ | ✓ | | | | 6 | 6 | 10 | 4 | 9 | 5 | 15 | 9 | 10 | 7 | 7 | 3 | |
| Inpatient Falls | Number of Inpatient Falls | Local | Apr-21 | 176 | | 12 month ↓ | ~ | | | $\sim \sim \sim$ | 193 | 209 | 196 | 208 | 227 | 219 | 187 | 247 | 247 | 203 | 177 | 171 | 176 |
| | % of universal mortality reviews (UMRs) undertaken within 28 days of a death | Local | Mar-21 | 98% | 95% | 95% | ~ | | | $\mathcal{N}^{\mathcal{N}}$ | 95.6% | 99.3% | 100.0% | 95.5% | 96.6% | 99.2% | 100.0% | 98.1% | 99.0% | 100.0% | 100.0% | 97.6% | |
| | Stage 2 mortality reviews required | Local | Mar-21 | 11 | | | | | | ~~~~ | 10 | 11 | 10 | 10 | 10 | 11 | 9 | 17 | 12 | 19 | 6 | 11 | |
| Mortality | % stage 2 mortality reviews completed | Local | Jan-21 | 36.80% | | 100% | × | | | | 30.0% | 27.3% | 50.0% | 90.0% | 50.0% | 54.5% | 33.3% | 35.7% | 75.0% | 36.8% | | | i |
| | Crude hospital mortality rate (74 years of age or less) | National | Mar-21 | 1.17% | 12 month 🗸 | | | 1.56% (Mar-21) | 4th (Mar-21) | | 0.80% | 0.88% | 0.89% | 0.92% | 0.90% | 0.93% | 0.97% | 1.01% | 1.08% | 1.14% | 1.17% | 1.17% | |
| | % of deaths scrutinised by a medical examiner | National | | | Qtr on qtr ↑ | | | | | | | | | | New me | asure for 20 | 20/21- await | ing data | | | | | |
| NEWS | % patients with completed NEWS scores & appropriate responses actioned | Local | Apr-21 | 97% | | 98% | × | | | \sim | 92.0% | 93.9% | 91.6% | 96.6% | 92.4% | 93.6% | 93.9% | 94.6% | 98.5% | 95.0% | 96.3% | 93.5% | 97.4% |
| HAT | Number of potentially preventable hospital acquired thromboses (HAT) | National | Q2 20/21 | 3 | 4 quarter ↓ | | | 6 | | | | | 3 | | | 3 | | | | | | | |
| | % of episodes clinically coded within 1 month of discharge | Local | Mar-21 | 96% | 95% | 95% | < | | | /~~ | 94% | 97% | 97% | 96% | 96% | 96% | 95% | 93% | 93% | 95% | 96% | 96% | |
| Coding | % of clinical coding accuracy attained in the NWIS national clinical coding accuracy audit programme | National | 2019/20 | 91% | Annual 🛧 | | | 93.9% (2019/20 | 7th (2019/20) | | | | | | | | | | | | | | |
| E-TOC | % of completed discharge summaries (total signed and sent) | Local | Apr-21 | 63% | | 100% | × | (| | ~~ <u>`</u> ~~ | 61% | 63% | 67% | 63% | 66% | 70% | 68% | 66% | 59% | 67% | 63% | 64% | 63% |
| | Agency spend as a % of the total pay bill | National | Aug-20 | 3.62% | 12 month 🗸 | | | 4.2% (Aug-20) | 5th out of 10 organisations (Aug-20) | • • | 4.04% | 3.21% | 4.32% | 2.81% | 3.62% | | | | | | | | |
| | Overall staff engagement score – scale score method | National | 2018 | 3.81 | Improvement | | | 3.82 (2018) | 7th out of 10 organisations (2018) | | | | | | | | | | | | | | |
| G | % of headcount by organisation who have had a PADR/medical appraisal in the previous 12 months (excluding doctors and dentists in training) | National | Apr-21 | 57% | 85% | 85% | × | 61.9% (Aug-20) | 7th out of 10 organisations (Aug-20) | | 68% | 63% | 60% | 59% | 58% | 58% | 58% | 56% | 54% | 52% | 51% | 53% | 57% |
| Workfor | % staff who undertook a performance appraisal who agreed it helped them improve how they do their job | National | 2018 | 55% | Improvement | | | 54% (2018) | 2nd (2018) | | | | | | | | | | | | | | |
| | % compliance for all completed Level 1 competency with the Core Skills and Training Framework | National | Apr-21 | 80% | 85% | 85% | × | 80.2% (Aug-20) | 7th out of 10 organisations (Aug-20) | \bigvee | 82% | 79% | 79% | 80% | 80% | 80% | 80% | 80% | 80% | 80% | 80% | 80% | 80% |
| | % workforce sickness absence (12 month rolling) | National | Mar-21 | 7.44% | 12 month ↓ | | | 5.92% (Aug-20) | 10th out of 10 organisations (Aug-20) | | 6.65% | 6.88% | 6.98% | 7.03% | 7.03% | 7.03% | 7.07% | 7.23% | 7.48% | 7.57% | 7.56% | 7.44% | |
| | % staff who would be happy with the standards of care provided by their organisation if a friend or relative needed treatment | National | 2018 | 72% | Improvement | | | 73% (2018) | 7th out of 10 organisations (2018) | | | | | | | | | | | | | | |

| Harm from reduction in non-Covid activity Sub Domain National or Local Target Period Profile Su's all- Vacal Profile Sub Courrent period National Target National Target National Target National Target Performance Trend Apr-20 May-20 Sep-20 Oct-20 Nov-20 Jan-21 Apr-21 % of GP practices that have achieved all standards set out in the target set | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|----------|----------------|---------|--------------------|------|---------------------|---------------------|---|--|---------|---------|---------|---------|---------|--------------|---------------|---------|---------|---------|---------|---------|---------|
| Sub Domain |) Measure | | | | | | | Average/ | | | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Apr-21 |
| | % of GP practices that have achieved all standards set out in the National Access Standards for in-hours GMS | National | 2019/20 | 38.80% | 100% | | | 59.7% (2019/20) | 7th (2019.20) | | | , | | | | 1 | | | | | 1 | | |
| Primary Care | % of children regularly accessing NHS primary dental care within 24 months | National | Q2 20/21 | 72.6% | 4 quarter ↑ | | | 63.8% (Q2 20/21) | 1st (Q2 20/21) | • | | | 75.9% | | | 72.6% | | | | | | | |
| | % adult dental patients in the health board population re- attending NHS primary dental care between 6 and 9 months | National | Mar-21 | 6.6% | 4 quarter 🗸 | | | 21.8% (Q3 20/21) | 1st (Q3 20/21) | \sim | 19.2% | 16.8% | 14.7% | 18.6% | 24.7% | 23.8% | 27.2% | 17.2% | 12.0% | 5.9% | 5.3% | 6.6% | |
| Cancer | % of patients starting definitive treatment within 62 days from point of suspicion (without adjustments) | National | Apr-21 (draft) | 47.6% | 12 month 🛧 | | | 61.2% (Jan-21) | 1st out of 6 organisations (Jan-21) | $\sim\sim\sim\sim$ | 54.7% | 61.8% | 59.9% | 68.2% | 67.4% | 62.4% | 65.9% | 55.4% | 61.0% | 67.9% | 56.4% | 71.6% | 47.6% |
| nes | Scheduled (21 Day Target) | Local | Apr-21 | 37% | 80% | | × | | | <u> </u> | 49% | 46% | 57% | 71% | 63% | 60% | 75% | 58% | 71% | 45% | 35% | 42% | 37% |
| ig tin | Scheduled (28 Day Target) | Local | Apr-21 | 77% | 100% | | × | | | -~~~~ | 86% | 84% | 93% | 97% | 92% | 86% | 90% | 85% | 88% | 82% | 80% | 85% | 77% |
| iting | Urgent SC (7 Day Target) | Local | Apr-21 | 38% | 80% | | × | | | $\sim\sim\sim\sim$ | 45% | 33% | 65% | 57% | 57% | 54% | 43% | 31% | 50% | 50% | 23% | 41% | 38% |
| N N S | Urgent SC (14 Day Target) | Local | Apr-21 | 83% | 100% | | × | | | $\checkmark \checkmark \checkmark \checkmark \sim$ | 91% | 83% | 90% | 97% | 91% | 92% | 86% | 100% | 85% | 94% | 91% | 90% | 83% |
| apy | Emergency (within 1 day) | Local | Apr-21 | 91% | 80% | | ✓ | | | \backslash | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 91% |
| ther | Emergency (within 2 days) | Local | Apr-21 | 100% | 100% | | < | | | | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| gio | Elective Delay (21 Day Target) | Local | Apr-21 | 82% | 80% | | < | | | ~~~~ | 76% | 83% | 92% | 52% | 46% | 58% | 58% | 56% | 71% | 69% | 61% | 86% | 82% |
| S. | Elective Delay (28 Day Target) | Local | Apr-21 | 92% | 100% | | × | | | $\sim \sim \sim$ | 88% | 100% | 100% | 97% | 75% | 60% | 75% | 73% | 88% | 89% | 75% | 93% | 92% |
| | Number of patients waiting > 8 weeks for a specified diagnostics | National | Apr-21 | 4,804 | 0 | | | 48,136 (Feb-21) | 2nd (Feb-21) | \sim | 5,788 | 8,346 | 8,033 | 7,510 | 8,070 | 7,666 | 6,645 | 6,610 | 6,579 | 6,239 | 5,087 | 4,554 | 4,804 |
| | Number of patients waiting > 14 weeks for a specified therapy | National | Apr-21 | 201 | 0 | | | 4,129 (Feb-21) | 3rd (Feb-21) | | 387 | 982 | 1,646 | 1,554 | 1,518 | 1,350 | 1,135 | 817 | 708 | 584 | 491 | 369 | 201 |
| | % of patients waiting < 26 weeks for treatment | National | Apr-21 | 49.1% | 95% | | | 51.6% (Feb-21) | 6th (Feb-21) | | 72.3% | 64.0% | 59.4% | 52.5% | 43.7% | 41.0% | 44.8% | 47.6% | 48.0% | 47.0% | 47.9% | 48.8% | 49.1% |
| d Care | Number of patients waiting > 26 weeks for outpatient appointment | Local | Apr-21 | 22,752 | 0 | | | | | | 5,499 | 9,300 | 11,964 | 15,721 | 20,497 | 23,069 | 22,050 | 21,005 | 21,179 | 21,208 | 21,225 | 21,750 | 22,752 |
| Planned | Number of patients waiting > 36 weeks for treatment | National | Apr-21 | 33,395 | 0 | | | 217,655 (Feb-21) | 3rd (Feb-21) | | 8,355 | 10,247 | 13,419 | 18,078 | 22,494 | 26,046 | 31,508 | 35,387 | 35,126 | 33,991 | 32,719 | 32,874 | 33,395 |
| Ē | The number of patients waiting for a follow-up outpatient appointment | National | Apr-21 | 122,303 | HB target TBC | | | 748,769 (Feb-21) | 5th (Feb-21) | \searrow | 123,082 | 121,434 | 120,468 | 120,062 | 120,969 | 120,962 | 120,968 | 120,874 | 119,963 | 119,999 | 120,882 | 121,403 | 122,303 |
| | The number of patients waiting for a follow-up outpatients appointment who are delayed over 100% | National | Apr-21 | 29,334 | TID target TDC | | | 199,704 (Feb-21) | 5th (Feb-21) | | 19,538 | 21,026 | 21,448 | 22,101 | 23,209 | 24,472 | 26,217 | 27,156 | 27,641 | 28,419 | 28,862 | 29,316 | 29,334 |
| | % of R1 ophthalmology patient pathways waiting within target date or within 25% beyond target date for an outpatient appointment | National | Mar-21 | 47.7% | 95% | | | 43.5% (Feb-21) | 3rd (Feb-21) | | 69.9% | 64.1% | 63.4% | 55.5% | 50.9% | 47.7% | 45.2% | 48.4% | 47.3% | 46.7% | 47.4% | 47.7% | |
| Hepatitis C | Number of patients with Hepatitis C who have successfully completed their course of treatment in the reporting year | National | | | HB target TBC | | | | | | | | | | New me | asure for 20 | 20/21- awaiti | ng data | | | 1 | | |
| DNAs | % of patients who did not attend a new outpatient appointment | Local | Apr-21 | 5.5% | 12 month 🗸 | | | | | $\checkmark \checkmark$ | 4.7% | 3.1% | 4.4% | 3.9% | 4.7% | 6.4% | 6.0% | 6.6% | 7.7% | 7.1% | 6.2% | 5.6% | 5.5% |
| ā | % of patients who did not attend a follow-up outpatient appointment | Local | Apr-21 | 6.2% | 12 month 🗸 | | | | | $\checkmark \frown \frown$ | 5.7% | 3.5% | 4.7% | 5.2% | 6.0% | 6.9% | 6.5% | 7.2% | 8.2% | 7.1% | 6.2% | 6.7% | 6.2% |
| Th . | Theatre Utilisation rates | Local | Apr-21 | 80.0% | | 90% | × | | | | 6% | 11% | 16% | 42% | 90% | 75% | 75% | 74% | 59% | 65% | 73% | 75% | 80% |
| Theatre Efficiencies | % of theatre sessions starting late | Local | Apr-21 | 38.0% | | <25% | × | | | ~~~~~ | 45% | 43% | 46% | 51% | 46% | 49% | 44% | 39% | 45% | 40% | 42% | 40% | 38% |
| Lindencies | % of theatre sessions finishing early | Local | Apr-21 | 41.0% | | <20% | × | | | $\sim \sim \sim \sim$ | 43% | 45% | 36% | 37% | 28% | 39% | 38% | 50% | 47% | 44% | 44% | 48% | 41% |
| Postponed operations | Number of procedures postponed either on the day or the day before for specified non-clinical reasons | National | Jan-21 | 1,200 | > 5% annual Ψ | | | 5,398 (Jan-21) | 6th (Jan-21) | ***** | 3,091 | 2,869 | 2,659 | 2,391 | 2,281 | 2,090 | 1,888 | 1,677 | 1,509 | 1,200 | | | |
| Treatment Fund | All new medicines must be made available no later than 2 months after NICE and AWMSG appraisals | National | Q2 20/21 | 98.8% | 100% | 100% | × | 98.3% (Q2 20/21) | 3rd out of 6 organisations (Q2 20/21) | | | | 98.7% | | | 98.8% | | | | | | | |

| Sub Domain Measure National or Report Current National Plan/ Profile Average/ Welsh SBU's all- Performance Apr-20 May-20 Jun-20 Jul-20 Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|-----------------------------|------------------|------------------------|------------------------------|-------------------------------|---------------------|----------------------------|--|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Sub Domain | n Measure | National or Local Target | Report Period | Current Performance | National Target | Annual Plan/ Local Profile | Profile Status | Welsh Average/ Total | SBU's all- Wales rank | Performance Trend | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Apr-21 |
| | Total antibacterial items per 1,000 STAR-PUs | National | Q3 20/21 | 258.8 | 4 quarter ↓ | | | 241.96 (Q3 20/21) | 6th (Q3 20/21) | | | | 243.8 | | | 249.9 | | | 258.8 | | | | |
| bu | Patients aged 65 years or over prescribed an antipsychotic | National | Q2 20/21 | 1,511 | Quarter on quarter 4 | | | 10,205 (Q2 20/21) | 5th (Q2 20/21) | • | | | 1,464 | | | 1,511 | | | | | | | |
| sscribi | Number of women of child bearing age prescribed valproate as a % of all women of child bearing age | National | Q2 20/21 | 0.23% | Quarter on quarter Ψ | | | 0.16% (Q2 20/21) | 7th (Q2 20/21) | * * | | | 0.23% | | | 0.23% | | | | | | | |
| Pre | Opioid average daily quantities per 1,000 patients | National | Q2 20/21 | 4,369 | 4 quarter ↓ | | | 4,390.4 (Q2 20/21) | 3rd (Q2 20/21) | • | | | 4,308 | | | 4,369 | | | | | | | |
| | Biosimilar medicines prescribed as % of total 'reference' product plus biosimilar | National | Q2 20/21 | 78.6% | Quarter on quarter ↑ | | | 82.6% (Q2 20/21) | 4th (Q2 20/21) | • | | | 80.2% | | | 78.6% | | | | | | | |
| | Average rating given by the public (age 16+) for the overall satisfaction with health services in Wales | National | 2018/19 | 6.4 | Annual 🛧 | | | 6.31 (2018/19) | 2nd (2018/19) | | | | | | | | | | • | • | | | |
| srience | % of adults (age 16+) who reported that they were very satisfied or fairly satisfied about the care that they received at their GP/family doctor | National | 2019/20 | 88.7% | Annual 🛧 | | | 88.6% (2019/20) | 3rd (2019/20) | | | | | | | | | | | | | | |
| tient expe | % of adults (age 16+) who reported that they were very satisfied or fairly satisfied about the care that they received at an NHS hospital (Local) | Local | 2018/19 | 92.9% | Annual 🛧 | | | | | | | | | | | | | | | | | | |
| Pai | Number of friends and family surveys completed | Local | Mar-21 | 1,050 | | 12 month 🛧 | ✓ | | | | 150 | 247 | 393 | 502 | 625 | 2,804 | 1,047 | 787 | 584 | 678 | 798 | 1,050 | |
| | % of who would recommend and highly recommend | Local | Mar-21 | 87% | | 90% | × | | | ~~~~ | 90% | 92% | 87% | 91% | 83% | 93% | 82% | 84% | 77% | 79% | 85% | 87% | |
| | % of all-Wales surveys scoring 9 out 10 on overall satisfaction | Local | Mar-21 | 93% | | 90% | ✓ | | | ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ | 95% | 100% | 79% | 91% | 83% | 84% | 79% | 85% | 65% | 81% | 94% | 93% | |
| lts | Number of new formal complaints received | Local | Apr-21 | 100 | | 12 month ↓ trend | × | | | | 37 | 52 | 73 | 77 | 74 | 107 | 121 | 103 | 83 | 78 | 94 | 117 | 100 |
| mplai | % concerns that had final reply (Reg 24)/interim reply (Reg 26) within 30 working days of concern received | National | Feb-21 | 80% | 75% | 80% | ~ | 71.9% (Q3 20/21) | 2nd (Q3 20/21) | $\sim \sim \sim$ | 81% | 81% | 75% | 79% | 72% | 82% | 75% | 82% | 80% | 71% | 80% | | |
| රි | % of acknowledgements sent within 2 working days | Local | Apr-21 | 100% | | 100% | ~ | | | | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| earch | Number of patients recruited in Health and Care Research Wales clinical research portfolio studies | National | Q1-Q3 20/21 | 1,328 | 10% annual ↑ | 1,651 | ~ | 6,378 (Q1-2 20/21) | 5th out of 10 organisations (Q1-2 20/21) | • • | | | 210 | | | 376 | | | 1328 | | | | |
| Rese | Number of patients recruited in Health and Care Research Wales commercially sponsored studies | nauonai | Q1-Q3 20/21 | 36 | 5% annual ↑ | 215 | × | 73 (Q1-2 20/21) | 2nd out of 10 organisations (Q1-2 20/21) | • | | | 2 | | | 21 | | | 36 | | | | |

| | | | | | | | Harm fro | om wider so | ocietal action | ns/lockdown | | | | | | | | | | | | | |
|-------------------------|--|-----------------------------|------------------|------------------------|---------------------|-------------------------------|-------------------|----------------------------|---|-------------------------|--------|---------|----------------|-------------|--------|--------|--------|--------|-------------|---------|--------|--------|--------------------------------|
| Sub Domain | Measure | National or Local Target | Report Period | Current Performance | National Target | Annual Plan/ Local Profile | Profile Status | Welsh Average/ Total | SBU's all- Wales rank | Performance Trend | Apr-20 | May-20 | Jun-20 | Jul-20 | Aug-20 | Sep-20 | Oct-20 | Nov-20 | Dec-20 | Jan-21 | Feb-21 | Mar-21 | Apr-21 |
| | % of babies who are exclusively breastfed at 10 days old | National | 2019/20 | 34.2% | Annual 🛧 | | | 35.3% (2019/20) | 5th (2019/20) | | | • | | | • | | | • | | · | • | • | |
| Early years measures | % children who received 3 doses of the hexavalent '6 in 1' vaccine by age 1 | National | Q3 20/21 | 96.7% | 95% | | | 95.3% (Q3 20/21) | 1st (Q3 20/21) | • | | | 96.5% | | | 96.5% | | | 96.7% | | | | |
| | % of children who received 2 doses of the MMR vaccine by age | National | Q3 20/21 | 92.0% | 95% | | | 92.1% (Q3 20/21) | 3rdh (Q3 20/21) | | | | 90.8% | | | 91.7% | | | 92.0% | | | | |
| Smoking cessation | % of adult smokers who make a quit attempt via smoking cessation services | National | Q1-Q2 20/21 | 1.66% | 5% annual target | | | 1.65% (Q1-2 20/21) | 4th (Q1-2 20/21) | ·. | | | | | | 1.66% | | | | | | | 1 |
| | European age standardised rate of alcohol attributed hospital admissions for individuals resident in Wales | National | Q3 20/21 | 308.8 | 4 quarter ↓ | | | 349.6 (Q3 20/21) | 2nd (Q3 20/21) | ••• | | | 279.6 | | | 331.7 | | | 308.8 | | | | |
| Alcohol | % of people who have been referred to health board services who have completed treatment for alcohol abuse | National | Q3 20/21 | 39.5% | 4 quarter ↑ | | | 64% (Q3 20/21) | 6th (Q2 20/21) | • | | | 32.8% | | | 23.2% | | | 39.5% | | | | |
| | % uptake of influenza among 65 year olds and over | National | Mar-21 | 75.5% | 75% | | | 76.5% (Mar-21) | 4th (Mar-21) | | | | - | 1 | | 1 | 65.6% | 72.4% | 74.8% | 75.2% | 75.4% | 75.5% | |
| | % uptake of influenza among under 65s in risk groups | National | Mar-21 | 49.4% | 55% | | | 51.07% (Mar-21) | 5th (Mar-21) | | | | | | | | 34.4% | 42.8% | 47.2% | 48.7% | 49.4% | 49.4% | Data |
| fluenza | % uptake of influenza among pregnant women | National | 2019/20 | 78.2% | 75% | | | 78.5% (2019/20) | 5th out of 10 organisations (2019/20) | | | Data co | llection resta | rts October | 2020 | | | | Data not av | ailable | | | Data collection restarts |
| 드 | % uptake of influenza among children 2 to 3 years old | Local | Mar-21 | 53.4% | 50% | | | 56.3% (Mar-21) | 5th (Mar-21) | | | | | | | | 35.7% | 48.8% | 52.5% | 53.2% | 53.4% | 53.4% | October 2021 |
| | % uptake of influenza among healthcare workers | National | Mar-21 | 63.4% | 60% | | | 58.7% (2019/20) | 7th out of 10 organisations (2019/20) | | | | | | | | 56.2% | 62.9% | 63.0% | 63.4% | 63.4% | 63.4% | |
| | Uptake of screening for bowel cancer | National | 2018/19 | 57.0% | 60% | | | 57.3% (2018/19) | 4th (2018/19) | | | | | | | | | | | | | | |
| Screening services | Uptake of screening for breast cancer | National | 2018/19 | 73.6% | 70% | | | 72.8% | 2nd (2018/19) | | | | | | | | | | | | | | |
| | Uptake of screening for cervical cancer | National | 2018/19 | 72.1% | 80% | | | 73.2% (2018/19) | 5th (2018/19) | | | | | | | | | | | | | | 1 |
| | % of urgent assessments undertaken within 48 hours from receipt of referral (Crisis) | Local | Mar-21 | 100% | | 100% | ~ | | | | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | |
| | % Patients with Neurodevelopmental Disorders (NDD) receiving a Diagnostic Assessment within 26 weeks | National | Mar-21 | 30% | 80% | 80% | × | 29.7% (Feb-21) | 5th (Feb-21) | $\searrow \checkmark$ | 35% | 30% | 28% | 30% | 24% | 21% | 22% | 24% | 26% | 24% | 28% | 30% | |
| | % Patients waiting less than 28 days for a first outpatient appointment for CAMHS | National | Mar-21 | 63% | 80% | 80% | × | 58.8% (Feb-21) | 4th (Feb-21) | $/ \sim$ | 44% | 78% | 100% | 100% | 100% | 98% | 90% | 88% | 61% | 53% | 66% | 63% | |
| CAMHS | P-CAMHS - % of Routine Assessment by CAMHS undertaken within 28 days from receipt of referral | National | Mar-21 | 46% | | 80% | × | 58.0% (Feb-21) | 1st (Feb-21) | \bigwedge | 11% | 89% | 100% | 100% | 100% | 62% | 29% | 41% | 73% | 29% | 97% | 46% | |
| | P-CAMHS - % of therapeutic interventions started within 28 days following assessment by LPMHSS | National | Mar-21 | 91% | | 80% | < | 75.3% (Feb-21) | 1st (Feb-21) | $(\land \land \land)$ | 85% | 100% | 100% | 100% | 86% | 100% | 100% | 100% | 100% | 93% | 97% | 91% | |
| | S-CAMHS - % of Routine Assessment by SCAMHS undertaken within 28 days from receipt of referral | Local | Mar-21 | 53% | | 80% | × | | | / | 46% | 72% | 100% | 100% | 100% | 98% | 79% | 62% | 58% | 60% | 56% | 53% | |
| | % residents in receipt of CAMHS to have a valid Care and Treatment Plan (CTP) | National | Mar-21 | 82% | | 90% | × | 82.3% (Feb-21) | 5th (Feb-21) | \sim | 99% | 97% | 91% | 98% | 98% | 81% | 82% | 81% | 82% | 83% | 84% | 82% | |
| | % of mental health assessments undertaken within (up to and including) 28 days from the date of receipt of referral (over 18 years of age) | National | Mar-21 | 97% | 80% | 80% | ~ | 81.3% (Feb-21) | 2nd (Feb-21) | $\sim \sim \sim$ | 99% | 99% | 100% | 99% | 99% | 97% | 99.5% | 98% | 99% | 96% | 98% | 97% | |
| Mental Health | % of therapeutic interventions started within (up to and including) 28 days following an assessment by LPMHSS (over 18 years of age) | National | Mar-21 | 97% | 80% | 80% | ~ | 83.0% (Feb-21) | 2nd (Feb-21) | \sim | 97% | 100% | 96% | 96% | 88% | 94% | 93% | 98% | 95% | 95% | 98% | 97% | |
| | % patients waiting < 26 weeks to start a psychological therapy in Specialist Adult Mental Health | National | Mar-21 | 100% | 95% | 95% | ~ | 60.0% (Feb-21) | 1st (Feb-21) | $\overline{\checkmark}$ | 93% | 89% | 84% | 89% | 91% | 99% | 99.7% | 100% | 100% | 100% | 100% | 100% | |
| | % residents in receipt of secondary MH services (all ages) who have a valid care and treatment plan (CTP) | National | Mar-21 | 91% | 90% | 90% | ~ | 85.5% (Feb-21) | 3rd (Feb-21) | $\checkmark \sim \sim$ | 93% | 92% | 92% | 94% | 92% | 90% | 91% | 91% | 89% | 91% | 91% | 91% | |
| Self harm | Rate of hospital admissions with any mention of intentional self- harm of children and young people (aged 10-24 years) | National | 2019/20 | 3.29 | Annual 🗸 | | | 3.97 (2019/20) | 4th (2019/20) | | | | | | | | | | | | | | |
| Dementia | % of people with dementia in Wales age 65 years or over who are diagnosed (registered on a GP QOF register) | National | 2018/19 | 59.4% | Annual 🛧 | | | 53.1% (2019/20) | 2nd (2019/20) | | | | | | | | | | | | | | |